File size: 232,874 Bytes
66ba51a |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818 2819 2820 2821 2822 2823 2824 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 2837 2838 2839 2840 2841 2842 2843 2844 2845 2846 2847 2848 2849 2850 2851 2852 2853 2854 2855 2856 2857 2858 2859 2860 2861 2862 2863 2864 2865 2866 2867 2868 2869 2870 2871 2872 2873 2874 2875 2876 2877 2878 2879 2880 2881 2882 2883 2884 2885 2886 2887 2888 2889 2890 2891 2892 2893 2894 2895 2896 2897 2898 2899 2900 2901 2902 2903 2904 2905 2906 2907 2908 2909 2910 2911 2912 2913 2914 2915 2916 2917 2918 2919 2920 2921 2922 2923 2924 2925 2926 2927 2928 2929 2930 2931 2932 2933 2934 2935 2936 2937 2938 2939 2940 2941 2942 2943 2944 2945 2946 2947 2948 2949 2950 2951 2952 2953 2954 2955 2956 2957 2958 2959 2960 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 2985 2986 2987 2988 2989 2990 2991 2992 2993 2994 2995 2996 2997 2998 2999 3000 3001 3002 3003 3004 3005 3006 3007 3008 3009 3010 3011 3012 3013 3014 3015 3016 3017 3018 3019 3020 3021 3022 3023 3024 3025 3026 3027 3028 3029 3030 3031 3032 3033 3034 3035 3036 3037 3038 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 3050 3051 3052 3053 3054 3055 3056 3057 3058 3059 3060 3061 3062 3063 3064 3065 3066 3067 3068 3069 3070 3071 3072 3073 3074 3075 3076 3077 3078 3079 3080 3081 3082 3083 3084 3085 3086 3087 3088 3089 3090 3091 3092 3093 3094 3095 3096 3097 3098 3099 3100 3101 3102 3103 3104 3105 3106 3107 3108 3109 3110 3111 3112 3113 3114 3115 3116 3117 3118 3119 3120 3121 3122 3123 3124 3125 3126 3127 3128 3129 3130 3131 3132 3133 3134 3135 3136 3137 3138 3139 3140 3141 3142 3143 3144 3145 3146 3147 3148 3149 3150 3151 3152 3153 3154 3155 3156 3157 3158 3159 3160 3161 3162 3163 3164 3165 3166 3167 3168 3169 3170 3171 3172 3173 3174 3175 3176 3177 3178 3179 3180 3181 3182 3183 3184 3185 3186 3187 3188 3189 3190 3191 3192 3193 3194 3195 3196 3197 3198 3199 3200 3201 3202 3203 3204 3205 3206 3207 3208 3209 3210 3211 3212 3213 3214 3215 3216 3217 3218 3219 3220 3221 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 3233 3234 3235 3236 3237 3238 3239 3240 3241 3242 3243 3244 3245 3246 3247 3248 3249 3250 3251 3252 3253 3254 3255 3256 3257 3258 3259 3260 3261 3262 3263 3264 3265 3266 3267 3268 3269 3270 3271 3272 3273 3274 3275 3276 3277 3278 3279 3280 3281 3282 3283 3284 3285 3286 3287 3288 3289 3290 3291 3292 3293 3294 3295 3296 3297 3298 3299 3300 3301 3302 3303 3304 3305 3306 3307 3308 3309 3310 3311 3312 3313 3314 3315 3316 3317 3318 3319 3320 3321 3322 3323 3324 3325 3326 3327 3328 3329 3330 3331 3332 3333 3334 3335 3336 3337 3338 3339 3340 3341 3342 3343 3344 3345 3346 3347 3348 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 3360 3361 3362 3363 3364 3365 3366 3367 3368 3369 3370 3371 3372 3373 3374 3375 3376 3377 3378 3379 3380 3381 3382 3383 3384 3385 3386 3387 3388 3389 3390 3391 3392 3393 3394 3395 3396 3397 3398 3399 3400 3401 3402 3403 3404 3405 3406 3407 3408 3409 3410 3411 3412 3413 3414 3415 3416 3417 3418 3419 3420 3421 3422 3423 3424 3425 3426 3427 3428 3429 3430 3431 3432 3433 3434 3435 3436 3437 3438 3439 3440 3441 3442 3443 3444 3445 3446 3447 3448 3449 3450 3451 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 3470 3471 3472 3473 3474 3475 3476 3477 3478 3479 3480 3481 3482 3483 3484 3485 3486 3487 3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 3531 3532 3533 3534 3535 3536 3537 3538 3539 3540 3541 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 3562 3563 3564 3565 3566 3567 3568 3569 3570 3571 3572 3573 3574 3575 3576 3577 3578 3579 3580 3581 3582 3583 3584 3585 3586 3587 3588 3589 3590 3591 3592 3593 3594 3595 3596 3597 3598 3599 3600 3601 3602 3603 3604 3605 3606 3607 3608 3609 3610 3611 3612 3613 3614 3615 3616 3617 3618 3619 3620 3621 3622 3623 3624 3625 3626 3627 3628 3629 3630 3631 3632 3633 3634 3635 3636 3637 3638 3639 3640 3641 3642 3643 3644 3645 3646 3647 3648 3649 3650 3651 3652 3653 3654 3655 3656 3657 3658 3659 3660 3661 3662 3663 3664 3665 3666 3667 3668 3669 3670 3671 3672 3673 3674 3675 3676 3677 3678 3679 3680 3681 3682 3683 3684 3685 3686 3687 3688 3689 3690 3691 3692 3693 3694 3695 3696 3697 3698 3699 3700 3701 3702 3703 3704 3705 3706 3707 3708 3709 3710 3711 3712 3713 3714 3715 3716 3717 3718 3719 3720 3721 3722 3723 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733 3734 3735 3736 3737 3738 3739 3740 3741 3742 3743 3744 3745 3746 3747 3748 3749 3750 3751 3752 3753 3754 3755 3756 3757 3758 3759 3760 3761 3762 3763 3764 3765 3766 3767 3768 3769 3770 3771 3772 3773 3774 3775 3776 3777 3778 3779 3780 3781 3782 3783 3784 3785 3786 3787 3788 3789 3790 3791 3792 3793 3794 3795 3796 3797 3798 3799 3800 3801 3802 3803 3804 3805 3806 3807 3808 3809 3810 3811 3812 3813 3814 3815 3816 3817 3818 3819 3820 3821 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 3838 3839 3840 3841 3842 3843 3844 3845 3846 3847 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 3858 3859 3860 3861 3862 3863 3864 3865 3866 3867 3868 3869 3870 3871 3872 3873 3874 3875 3876 3877 3878 3879 3880 3881 3882 3883 3884 3885 3886 3887 3888 3889 3890 3891 3892 3893 3894 3895 3896 3897 3898 3899 3900 3901 3902 3903 3904 3905 3906 3907 3908 3909 3910 3911 3912 3913 3914 3915 3916 3917 3918 3919 3920 3921 3922 3923 3924 3925 3926 3927 3928 3929 3930 3931 3932 3933 3934 3935 3936 3937 3938 3939 3940 3941 3942 3943 3944 3945 3946 3947 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 3985 3986 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 4063 4064 4065 4066 4067 4068 4069 4070 4071 4072 4073 4074 4075 4076 4077 4078 4079 4080 4081 4082 4083 4084 4085 4086 4087 4088 4089 4090 4091 4092 4093 4094 4095 4096 4097 4098 4099 4100 4101 4102 4103 4104 4105 4106 4107 4108 4109 4110 4111 4112 4113 4114 4115 4116 4117 4118 4119 4120 4121 4122 4123 4124 4125 4126 4127 4128 4129 4130 4131 4132 4133 4134 4135 4136 4137 4138 4139 4140 4141 4142 4143 4144 4145 4146 4147 4148 4149 4150 4151 4152 4153 4154 4155 4156 4157 4158 4159 4160 4161 4162 4163 4164 4165 4166 4167 4168 4169 4170 4171 4172 4173 4174 4175 4176 4177 4178 4179 4180 4181 4182 4183 4184 4185 4186 4187 4188 4189 4190 4191 4192 4193 4194 4195 4196 4197 4198 4199 4200 4201 4202 4203 4204 4205 4206 4207 4208 4209 4210 4211 4212 4213 4214 4215 4216 4217 4218 4219 4220 4221 4222 4223 4224 4225 4226 4227 4228 4229 4230 4231 4232 4233 4234 4235 4236 4237 4238 4239 4240 4241 4242 4243 4244 4245 4246 4247 4248 4249 4250 4251 4252 4253 4254 4255 4256 4257 4258 4259 4260 4261 4262 4263 4264 4265 4266 4267 4268 4269 4270 4271 4272 4273 4274 4275 4276 4277 4278 4279 4280 4281 4282 4283 4284 4285 4286 4287 4288 4289 4290 4291 4292 4293 4294 4295 4296 4297 4298 4299 4300 4301 4302 4303 4304 4305 4306 4307 4308 4309 4310 4311 4312 4313 4314 4315 4316 4317 4318 4319 4320 4321 4322 4323 4324 4325 4326 4327 4328 4329 4330 4331 4332 4333 4334 4335 4336 4337 4338 4339 4340 4341 4342 4343 4344 4345 4346 4347 4348 4349 4350 4351 4352 4353 4354 4355 4356 4357 4358 4359 4360 4361 4362 4363 4364 4365 4366 4367 4368 4369 4370 4371 4372 4373 4374 4375 4376 4377 4378 4379 4380 4381 4382 4383 4384 4385 4386 4387 4388 4389 4390 4391 4392 4393 4394 4395 4396 4397 4398 4399 4400 4401 4402 4403 4404 4405 4406 4407 4408 4409 4410 4411 4412 4413 4414 4415 4416 4417 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 4588 4589 |
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<tmx version="1.4">
<header adminlang="en" creationdate="20200424T153631Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="hr">
<prop type="distributor">ELRC project</prop>
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Maligna aligner was used for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop>
<prop type="l1">hr</prop>
<prop type="l2">en</prop>
<prop type="lengthInTUs">508</prop>
<prop type="# of words in l1">7794</prop>
<prop type="# of words in l2">7465</prop>
<prop type="# of unique words in l1">1524</prop>
<prop type="# of unique words in l2">2292</prop>
</header>
<body>
<tu tuid="1">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>Immunity usually lasts for years, and sometimes for a lifetime.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Imunitet obično traje godinama, a ponekad i čitav život.</seg>
</tuv>
</tu>
<tu tuid="2">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>This is called the antigen.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Njegov je naziv antigen.</seg>
</tuv>
</tu>
<tu tuid="3">
<prop type="lengthRatio">0.8627450980392157</prop>
<tuv xml:lang="en">
<seg>The person is also at risk of complications.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ta je osoba tada izložena i riziku od komplikacija.</seg>
</tuv>
</tu>
<tu tuid="4">
<prop type="lengthRatio">0.85</prop>
<tuv xml:lang="en">
<seg>How vaccines work</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako djeluju cjepiva</seg>
</tuv>
</tu>
<tu tuid="5">
<prop type="lengthRatio">1.2093023255813953</prop>
<tuv xml:lang="en">
<seg>The length of time varies by disease and by vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Duljina trajanja ovisi o bolesti i cjepivu.</seg>
</tuv>
</tu>
<tu tuid="6">
<prop type="lengthRatio">0.8222222222222222</prop>
<tuv xml:lang="en">
<seg>This ‘ community immunity ' can only work if enough people are vaccinated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Taj imunitet zajednice može funkcionirati samo onda kada je cijepljen dovoljan broj osoba.</seg>
</tuv>
</tu>
<tu tuid="7">
<prop type="lengthRatio">1.0509554140127388</prop>
<tuv xml:lang="en">
<seg>Vaccines contain a greatly weakened or an inactivated (killed) form of a virus or bacterium that usually causes a disease, or a small part of the virus or bacterium.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo sadržava jako oslabljeni ili inaktivirani (mrtvi) oblik virusa ili bakterije koji obično izazivaju bolest ili samo mali dio tog virusa ili bakterije.</seg>
</tuv>
</tu>
<tu tuid="8">
<prop type="lengthRatio">1.1329113924050633</prop>
<tuv xml:lang="en">
<seg>Immunity through vaccination protects not only the immunised individual but also protects unvaccinated people in the community, such as infants who are too young to be vaccinated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Imunitet koji steknemo cijepljenjem ne štiti samo cijepljenu osobu, već i osobe koje nisu cijepljene u zajednici, poput djece koja su premlada za cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="9">
<prop type="lengthRatio">0.9262672811059908</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood, in the bone marrow and all over the body, called T-cells, B-cells, among others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaki virus i svaka bakterija izazivaju jedinstven odgovor imunosnog sustava u koji je uključen određeni skup stanica u krvi, u koštanoj srži i u čitavom tijelu, koje su među ostalim poznate kao T-stanice i B-stanice.</seg>
</tuv>
</tu>
<tu tuid="10">
<prop type="lengthRatio">1.05</prop>
<tuv xml:lang="en">
<seg>Later, if the person comes into contact with the actual infectious virus or bacterium, their immune system will ‘remember' it.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako osoba kasnije dođe u kontakt sa stvarnim infektivnim virusom ili bakterijom, njezin će se imunosni sustav „sjetiti".</seg>
</tuv>
</tu>
<tu tuid="11">
<prop type="lengthRatio">1.1226415094339623</prop>
<tuv xml:lang="en">
<seg>A vaccine stimulates an immune response, and a ‘memory' of the body to a specific disease, without causing the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo stimulira imunosni odgovor, a tijelo stvara „pamćenje" o određenoj bolesti bez toga da je izazove.</seg>
</tuv>
</tu>
<tu tuid="12">
<prop type="lengthRatio">1.0064102564102564</prop>
<tuv xml:lang="en">
<seg>It will then quickly produce the right antibodies and activate the right immune cells to kill the virus or bacterium, protecting the person from the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon toga vrlo brzo proizvest će protutijela i aktivirati ispravne imunosne stanice koje će uništiti virus ili bakteriju i tako zaštititi osobu od bolesti.</seg>
</tuv>
</tu>
<tu tuid="13">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>When a person is given the vaccine, their immune system recognises the antigen as ‘foreign'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada osoba primi cjepivo, njezin imunosni sustav prepoznaje antigen kao „strano tijelo".</seg>
</tuv>
</tu>
<tu tuid="14">
<prop type="lengthRatio">0.9133858267716536</prop>
<tuv xml:lang="en">
<seg>In contrast, a person who becomes immune by getting the disease can expose other unvaccinated people to the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>S druge strane, osoba koja imunitet stekne obolijevanjem može druge osobe koje nisu cijepljene izložiti riziku od obolijevanja.</seg>
</tuv>
</tu>
<tu tuid="15">
<prop type="lengthRatio">0.9578947368421052</prop>
<tuv xml:lang="en">
<seg>The immune cells are trained to kill and make antibodies against the disease-causing agent.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stanice imunosnog sustava obučene su da uništavaju i stvaraju protutijela za uzročnika bolesti.</seg>
</tuv>
</tu>
<tu tuid="16">
<prop type="lengthRatio">0.8395061728395061</prop>
<tuv xml:lang="en">
<seg>Antibodies are special proteins that help kill the infectious agent.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Protutijela su posebne bjelančevine koje pridonose uništavanju uzročnika bolesti.</seg>
</tuv>
</tu>
<tu tuid="17">
<prop type="lengthRatio">1.9375</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Sastojci cjepiva</seg>
</tuv>
</tu>
<tu tuid="18">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Trusted sources</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pouzdani izvori</seg>
</tuv>
</tu>
<tu tuid="19">
<prop type="lengthRatio">0.9421487603305785</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ovaj dio pruža linkove do web stranica drugih zdravstvenih organizacija kako na nacionalnoj tako i na međunarodnoj razini</seg>
</tuv>
</tu>
<tu tuid="20">
<prop type="lengthRatio">0.8863636363636364</prop>
<tuv xml:lang="en">
<seg>European Vaccination Information Portal</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europski portal za informacije o cijepljenju</seg>
</tuv>
</tu>
<tu tuid="21">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U Europi se gripa javlja...</seg>
</tuv>
</tu>
<tu tuid="22">
<prop type="lengthRatio">0.9491525423728814</prop>
<tuv xml:lang="en">
<seg>Vaccines protect people during different stages of life.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivima se štiti ljude u različitim životnim razdobljima.</seg>
</tuv>
</tu>
<tu tuid="23">
<prop type="lengthRatio">0.7153284671532847</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije nego što se cjepivo može odobriti u EU-u, ono mora biti podvrgnuto strogom ispitivanju koje provodi subjekt koji razvija cjepivo...</seg>
</tuv>
</tu>
<tu tuid="24">
<prop type="lengthRatio">0.9606299212598425</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaki virus i svaka bakterija izazivaju jedinstven odgovor imunosnog sustava u koji je uključen određeni skup stanica u krvi...</seg>
</tuv>
</tu>
<tu tuid="25">
<prop type="lengthRatio">1.1625</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se osobe štiti od bolesti koje mogu imati ozbiljne posljedice za...</seg>
</tuv>
</tu>
<tu tuid="26">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>Approval of vaccines in the European Union</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Odobrenje cjepiva u Europskoj uniji</seg>
</tuv>
</tu>
<tu tuid="27">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Gripa (influenca) zarazna je bolest dišnih puteva uzrokovana infekcijom virusom influence.</seg>
</tuv>
</tu>
<tu tuid="28">
<prop type="lengthRatio">1.0404040404040404</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se štiti i cijepljene osobe i osobe iz njihova okruženja koje su podložne bolestima...</seg>
</tuv>
</tu>
<tu tuid="29">
<prop type="lengthRatio">1.3076923076923077</prop>
<tuv xml:lang="en">
<seg>When to vaccinate</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada cijepiti</seg>
</tuv>
</tu>
<tu tuid="30">
<prop type="lengthRatio">1.1470588235294117</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for individuals</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pojedinačne koristi od cijepljenja</seg>
</tuv>
</tu>
<tu tuid="31">
<prop type="lengthRatio">0.8653846153846154</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva se preporučuju za različite dobne skupine...</seg>
</tuv>
</tu>
<tu tuid="32">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>Read more About us .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više o cijepljenju</seg>
</tuv>
</tu>
<tu tuid="33">
<prop type="lengthRatio">1.1714285714285715</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for the community</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koristi od cijepljenja za zajednicu</seg>
</tuv>
</tu>
<tu tuid="34">
<prop type="lengthRatio">1.3717948717948718</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac je vrlo zarazna bakterijska bolest koja zahvaća pluća i dišne putove.</seg>
</tuv>
</tu>
<tu tuid="35">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>About us</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac</seg>
</tuv>
</tu>
<tu tuid="36">
<prop type="lengthRatio">1.1217391304347826</prop>
<tuv xml:lang="en">
<seg>It typically provides lifelong protection and has an effectiveness of around 97-99% among healthy children who receive two doses.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ono obično nudi cjeloživotnu zaštitu i djelotvornost mu je oko 97 - 99 % među zdravom djecom koja prime dvije doze.</seg>
</tuv>
</tu>
<tu tuid="37">
<prop type="lengthRatio">0.7166666666666667</prop>
<tuv xml:lang="en">
<seg>They are also less likely to infect others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Također je manja vjerojatnost da će te osobe zaraziti druge.</seg>
</tuv>
</tu>
<tu tuid="38">
<prop type="lengthRatio">0.7368421052631579</prop>
<tuv xml:lang="en">
<seg>These include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U njih se ubrajaju:</seg>
</tuv>
</tu>
<tu tuid="39">
<prop type="lengthRatio">0.889763779527559</prop>
<tuv xml:lang="en">
<seg>Vaccines prevent diseases that could otherwise cause serious health problems, permanent disability or even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivima se sprječavaju bolesti koje bi inače mogle uzrokovati ozbiljne zdravstvene probleme, trajni invaliditet ili čak smrt.</seg>
</tuv>
</tu>
<tu tuid="40">
<prop type="lengthRatio">0.896551724137931</prop>
<tuv xml:lang="en">
<seg>As with any medicine, no vaccine is 100% effective in every person vaccinated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kao i drugi lijekovi, nijedno cjepivo nije 100 % djelotvorno za svaku cijepljenu osobu.</seg>
</tuv>
</tu>
<tu tuid="41">
<prop type="lengthRatio">1.0238095238095237</prop>
<tuv xml:lang="en">
<seg>other diseases or conditions they may have;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>druge eventualne bolesti ili druga stanja;</seg>
</tuv>
</tu>
<tu tuid="42">
<prop type="lengthRatio">0.8539325842696629</prop>
<tuv xml:lang="en">
<seg>Individual European countries decide which vaccines should be part of their national vaccination programmes and funded by their national health systems.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka europska zemlja pojedinačno odlučuje o tome koja će cjepiva činiti dio njezina nacionalnog programa cijepljenja i financirati iz sredstava nacionalnih zdravstvenih sustava.</seg>
</tuv>
</tu>
<tu tuid="43">
<prop type="lengthRatio">1.0603448275862069</prop>
<tuv xml:lang="en">
<seg>In some circumstances, a person can still get a disease even after receiving the recommended doses of a vaccine against it.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U određenim okolnostima osoba se ipak može zaraziti bolešću nakon primanja preporučenih doza cjepiva protiv bolesti.</seg>
</tuv>
</tu>
<tu tuid="44">
<prop type="lengthRatio">1.2653061224489797</prop>
<tuv xml:lang="en">
<seg>Effectiveness in an individual depends on a number of factors.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pojedinačna djelotvornost ovisi o nizu čimbenika.</seg>
</tuv>
</tu>
<tu tuid="45">
<prop type="lengthRatio">1.0165289256198347</prop>
<tuv xml:lang="en">
<seg>This is due to the person not developing sufficient protection against the disease or due to immunity decreasing over time.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To se događa jer osoba nije razvila dovoljan stupanj zaštite od bolesti ili zbog toga što je imunitet s vremenom oslabio.</seg>
</tuv>
</tu>
<tu tuid="46">
<prop type="lengthRatio">1.0093457943925233</prop>
<tuv xml:lang="en">
<seg>For example, the vaccine against measles, mumps and rubella (MMR) is highly effective at preventing disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Primjerice, cjepivo protiv ospica, zaušnjaka i rubeole (MMR) iznimno je djelotvorno u sprječavanju bolesti.</seg>
</tuv>
</tu>
<tu tuid="47">
<prop type="lengthRatio">1.5</prop>
<tuv xml:lang="en">
<seg>the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>cjepivo.</seg>
</tuv>
</tu>
<tu tuid="48">
<prop type="lengthRatio">0.9035532994923858</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon što je cjepivo odobreno za korištenje, nacionalna nadležna tijela u državama EU-a / EGP-a i Europska agencija za lijekove (EMA) kontinuirano prate nuspojave kod osoba koje su primile cjepivo.</seg>
</tuv>
</tu>
<tu tuid="49">
<prop type="lengthRatio">0.9482758620689655</prop>
<tuv xml:lang="en">
<seg>In these cases, however, the person's symptoms are often milder than they would have been without vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tim su slučajevima, međutim, simptomi bolesti često blaži od simptoma koji bi se razvili da nije bilo cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="50">
<prop type="lengthRatio">0.9122807017543859</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety and reporting side effects</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Praćenje sigurnosti cjepiva i izvješćivanje o nuspojavama</seg>
</tuv>
</tu>
<tu tuid="51">
<prop type="lengthRatio">1.0128205128205128</prop>
<tuv xml:lang="en">
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djelotvornost cjepiva određuje njegova sposobnost da spriječi određenu bolest.</seg>
</tuv>
</tu>
<tu tuid="52">
<prop type="lengthRatio">1.0654205607476634</prop>
<tuv xml:lang="en">
<seg>Authorised vaccines are effective at preventing disease and protecting the population when administered correctly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako se pravilno primjenjuju, odobrena cjepiva djelotvorna su u sprječavanju bolesti i zaštiti stanovništva.</seg>
</tuv>
</tu>
<tu tuid="53">
<prop type="lengthRatio">1.1363636363636365</prop>
<tuv xml:lang="en">
<seg>how the vaccine is given;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>način davanja cjepiva;</seg>
</tuv>
</tu>
<tu tuid="54">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koristi cijepljenja</seg>
</tuv>
</tu>
<tu tuid="55">
<prop type="lengthRatio">1.0625</prop>
<tuv xml:lang="en">
<seg>previous contact with the disease;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>vrijeme proteklo od cijepljenja;</seg>
</tuv>
</tu>
<tu tuid="56">
<prop type="lengthRatio">0.9642857142857143</prop>
<tuv xml:lang="en">
<seg>National governments take account of factors such as their health systems, legal systems and cultural norms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nacionalne vlade uzimaju u obzir čimbenike poput svojih zdravstvenih sustava, pravnih sustava i kulturnih normi.</seg>
</tuv>
</tu>
<tu tuid="57">
<prop type="lengthRatio">1.0285714285714285</prop>
<tuv xml:lang="en">
<seg>Mandatory or recommended vaccination</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Obvezno ili preporučeno cijepljenje</seg>
</tuv>
</tu>
<tu tuid="58">
<prop type="lengthRatio">1.0294117647058822</prop>
<tuv xml:lang="en">
<seg>Vaccination schedules in the EU/EEA</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rasporedi cijepljenja u EU-u/EGP-u</seg>
</tuv>
</tu>
<tu tuid="59">
<prop type="lengthRatio">1.0065359477124183</prop>
<tuv xml:lang="en">
<seg>In 12 EU/EEA countries, vaccinating children against some diseases is mandatory, although different vaccines are required as mandatory in those countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U 12 država EU-a/EGP-a cijepljenje djece protiv određenih bolesti je obvezno, iako postoje razlike u pogledu toga koja su cjepiva u tim zemljama obvezna.</seg>
</tuv>
</tu>
<tu tuid="60">
<prop type="lengthRatio">0.9393939393939394</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country implements its own immunisation programme.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka država EU-a/EGP-a provodi svoj vlastiti program imunizacije.</seg>
</tuv>
</tu>
<tu tuid="61">
<prop type="lengthRatio">0.7678571428571429</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country decides if vaccination is mandatory or voluntary in its territory.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka država EU-a/EGP-a odlučuje o tome je li cijepljenje obvezno ili dobrovoljno na njezinom državnom području.</seg>
</tuv>
</tu>
<tu tuid="62">
<prop type="lengthRatio">1.0104166666666667</prop>
<tuv xml:lang="en">
<seg>Information on which countries have mandatory vaccination can be found in the Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Informacije o tome u kojim je državama cijepljenje obvezno možete pronaći urasporedu cijepljenja</seg>
</tuv>
</tu>
<tu tuid="63">
<prop type="lengthRatio">1.05</prop>
<tuv xml:lang="en">
<seg>Most EU/EEA countries offer vaccination on a recommended basis.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina država EU-a/EGP-a nudi cijepljenje na bazi preporuke.</seg>
</tuv>
</tu>
<tu tuid="64">
<prop type="lengthRatio">1.168421052631579</prop>
<tuv xml:lang="en">
<seg>EU/EEA countries have achieved high vaccination coverage rates through mandatory and non-mandatory vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Države EU-a/EGP-a postigle su obveznim i neobveznim cijepljenjem visoke stope procijepljenosti.</seg>
</tuv>
</tu>
<tu tuid="65">
<prop type="lengthRatio">1.0952380952380953</prop>
<tuv xml:lang="en">
<seg>This is offered to women in accordance with national recommendations.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postupak je dostupan ženama u skladu s nacionalnim preporukama.</seg>
</tuv>
</tu>
<tu tuid="66">
<prop type="lengthRatio">0.9292035398230089</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija potražite na mrežnom mjestu ECDC-a: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
</tu>
<tu tuid="67">
<prop type="lengthRatio">1.088235294117647</prop>
<tuv xml:lang="en">
<seg>If HPV does not go away it may cause:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako HPV ne nestane, može izazvati:</seg>
</tuv>
</tu>
<tu tuid="68">
<prop type="lengthRatio">1.05</prop>
<tuv xml:lang="en">
<seg>It is the most common sexually transmitted infection worldwide.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Riječ je o najčešćoj spolno prenosivoj infekciji na svijetu.</seg>
</tuv>
</tu>
<tu tuid="69">
<prop type="lengthRatio">0.8913043478260869</prop>
<tuv xml:lang="en">
<seg>About 40 of them can infect the genitals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Oko 40 njih može izazvati genitalne infekcije.</seg>
</tuv>
</tu>
<tu tuid="70">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>There is no treatment for the virus itself, but the health problems caused by HPV can be treated in different ways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ne postoji lijek za sami virus, ali zdravstveni problemi izazvani HPV-om mogu se liječiti na različite načine.</seg>
</tuv>
</tu>
<tu tuid="71">
<prop type="lengthRatio">1.0510204081632653</prop>
<tuv xml:lang="en">
<seg>In most cases, an HPV infection disappears on its own without causing any obvious symptoms or problems.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U većini slučajeva infekcija HPV-om nestaje sama od sebe i ne izaziva očite simptome ili probleme.</seg>
</tuv>
</tu>
<tu tuid="72">
<prop type="lengthRatio">1.103448275862069</prop>
<tuv xml:lang="en">
<seg>Routine HPV vaccination usually takes place between 9 and 14 years of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rutinsko cijepljenje protiv HPV-a obavlja se u dobi od 9 do 14 godina, u skladu s nacionalnim programom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="73">
<prop type="lengthRatio">0.8712121212121212</prop>
<tuv xml:lang="en">
<seg>However, sometimes the HPV infection can persist and cause after some years some of the complications listed below.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, infekcije HPV-om ponekad mogu biti tvrdokorne i izazvati, nakon nekoliko godina, neke od komplikacija navedenih u nastavku.</seg>
</tuv>
</tu>
<tu tuid="74">
<prop type="lengthRatio">0.9183673469387755</prop>
<tuv xml:lang="en">
<seg>There are more than 100 types of HPV viruses.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postoji više od 100 vrsta humanih papilomavirusa.</seg>
</tuv>
</tu>
<tu tuid="75">
<prop type="lengthRatio">1.0225563909774436</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact with an infected person.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Infekcija humanim papilomavirusom (HPV) virusna je infekcija koja se uglavnom prenosi izravnim spolnim kontaktom sa zaraženom osobom.</seg>
</tuv>
</tu>
<tu tuid="76">
<prop type="lengthRatio">0.8650306748466258</prop>
<tuv xml:lang="en">
<seg>Other HPV-related cancers are also more treatable when diagnosed and treated early, but there are no specific screening programmes for these.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>I liječenje drugih vrsta raka povezanih s HPV-om uspješnije je ako se bolest dijagnosticira i liječi u ranoj fazi, ali za njih ne postoje posebni programi probira.</seg>
</tuv>
</tu>
<tu tuid="77">
<prop type="lengthRatio">0.9767441860465116</prop>
<tuv xml:lang="en">
<seg>HPV is transmitted by direct contact, mainly sexual, with someone who has the virus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>HPV se prenosi izravnim kontaktom, uglavnom spolnim, s osobom koja je nositelj virusa.</seg>
</tuv>
</tu>
<tu tuid="78">
<prop type="lengthRatio">0.8787878787878788</prop>
<tuv xml:lang="en">
<seg>A healthcare provider should be consulted for advice on the specific treatment options.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za savjet o specifičnim mogućnostima liječenja potrebno se obratiti pružatelju zdravstvene zaštite.</seg>
</tuv>
</tu>
<tu tuid="79">
<prop type="lengthRatio">0.8607594936708861</prop>
<tuv xml:lang="en">
<seg>Vaccination of girls and boys against HPV can prevent HPV infections and consequently HPV-related diseases in both sexes, including genital and anal warts, cervical cancer and other cancers caused by HPV.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem dječaka i djevojčica protiv HPV-a mogu se spriječiti infekcije HPV-om i, posljedično, bolesti povezane s HPV-om u oba spola, kao što su genitalne i analne bradavice, rak grlića maternice i druge vrste raka uzrokovane HPV-om.</seg>
</tuv>
</tu>
<tu tuid="80">
<prop type="lengthRatio">0.6666666666666666</prop>
<tuv xml:lang="en">
<seg>Genital warts can be treated using medication or by surgery.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako je riječ o genitalnim bradavicama, mogu se primijeniti lijekovi ili kirurški postupak.</seg>
</tuv>
</tu>
<tu tuid="81">
<prop type="lengthRatio">0.8145161290322581</prop>
<tuv xml:lang="en">
<seg>At least 14 HPV types, classified as ‘high risk', can cause cancer, such as cervical cancer in women.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Najmanje 14 vrsta HPV-a pripada u skupinu „visokorizičnih" jer mogu prouzročiti rak, kao što je rak grlića maternice u žena.</seg>
</tuv>
</tu>
<tu tuid="82">
<prop type="lengthRatio">0.9375</prop>
<tuv xml:lang="en">
<seg>Anyone who is sexually active is at risk of contracting HPV.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Sve spolno aktivne osobe izložene su riziku od infekcije HPV-om.</seg>
</tuv>
</tu>
<tu tuid="83">
<prop type="lengthRatio">0.9655172413793104</prop>
<tuv xml:lang="en">
<seg>cervical or other types of cancer (e.g. vulvar, vaginal, anal penile, and some cancers of the head and the neck)</seg>
</tuv>
<tuv xml:lang="hr">
<seg>rak grlića maternice ili druge vrste raka (npr. rak stidnice, rodnice, anusa, penisa i neke vrste raka glave i vrata</seg>
</tuv>
</tu>
<tu tuid="84">
<prop type="lengthRatio">0.8529411764705882</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi infekcije HPV-om?</seg>
</tuv>
</tu>
<tu tuid="85">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>How is HPV treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se HPV liječi?</seg>
</tuv>
</tu>
<tu tuid="86">
<prop type="lengthRatio">1.3867924528301887</prop>
<tuv xml:lang="en">
<seg>Cervical cancer and tissue in the cervix that is described as ‘precancerous' can be identified early through cervical cancer screening and treated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rak i pretkancerogeno tkivo u području grlića maternice moguće je rano otkriti metodom probira i liječiti.</seg>
</tuv>
</tu>
<tu tuid="87">
<prop type="lengthRatio">0.7857142857142857</prop>
<tuv xml:lang="en">
<seg>genital and anal warts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>genitalne i analne bradavice</seg>
</tuv>
</tu>
<tu tuid="88">
<prop type="lengthRatio">0.7096774193548387</prop>
<tuv xml:lang="en">
<seg>Who is at risk of HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od HPV-a?</seg>
</tuv>
</tu>
<tu tuid="89">
<prop type="lengthRatio">0.6097560975609756</prop>
<tuv xml:lang="en">
<seg>How can HPV be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se infekcija HPV-om može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="90">
<prop type="lengthRatio">0.5604395604395604</prop>
<tuv xml:lang="en">
<seg>This is because HPV can also occasionally infect surrounding skin that is not protected by the condom.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Upotreba prezervativa nije 100 % djelotvorna u pogledu sprječavanja prijenosa virusa. zbog toga što HPV-om ponekad može biti zaražena i okolna koža koja nije zaštićena prezervativom.</seg>
</tuv>
</tu>
<tu tuid="91">
<prop type="lengthRatio">0.7727272727272727</prop>
<tuv xml:lang="en">
<seg>What are the complications of HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su moguće komplikacije izazvane HPV-om?</seg>
</tuv>
</tu>
<tu tuid="92">
<prop type="lengthRatio">0.7160493827160493</prop>
<tuv xml:lang="en">
<seg>The 'low risk' HPV types can cause genital and anal warts.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>„Niskorizične" vrste HPV-a mogu dovesti do pojave genitalnih i analnih bradavica.</seg>
</tuv>
</tu>
<tu tuid="93">
<prop type="lengthRatio">0.5725806451612904</prop>
<tuv xml:lang="en">
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rak grlića maternice najčešća je vrsta raka, nakon raka dojke, od koje obolijevaju žene u Europi u dobi od 15 do 44 godine (1). „Visokorizične" vrste HPV-a mogu uzrokovati i rak anusa i genitalija te neke vrste raka glave i vrata, neovisno o spolu.</seg>
</tuv>
</tu>
<tu tuid="94">
<prop type="lengthRatio">0.9565217391304348</prop>
<tuv xml:lang="en">
<seg>It can spread quickly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Može se brzo proširiti.</seg>
</tuv>
</tu>
<tu tuid="95">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Less than 5% will have fever.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Manje od 5 % imat će vrućicu.</seg>
</tuv>
</tu>
<tu tuid="96">
<prop type="lengthRatio">0.96875</prop>
<tuv xml:lang="en">
<seg>Measles had almost been eliminated in many European countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice su bile gotovo iskorijenjene u mnogim europskim zemljama.</seg>
</tuv>
</tu>
<tu tuid="97">
<prop type="lengthRatio">1.45</prop>
<tuv xml:lang="en">
<seg>Therefore, the long-term benefits of getting vaccinated may not be immediately obvious.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stoga dugotrajne koristi cijepljenja možda nisu odmah očite.</seg>
</tuv>
</tu>
<tu tuid="98">
<prop type="lengthRatio">1.1297709923664123</prop>
<tuv xml:lang="en">
<seg>It will often lead to hospitalisation in infants, and the risk of complications and hospitalisation increases for infants younger than three months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djecu se zbog njega često mora hospitalizirati, a opasnost od komplikacija i hospitalizacije veća je za djecu mlađu od tri mjeseca.</seg>
</tuv>
</tu>
<tu tuid="99">
<prop type="lengthRatio">0.8952380952380953</prop>
<tuv xml:lang="en">
<seg>If people stopped being vaccinated, many of these diseases and related outbreaks could return.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako bi se ljudi prestali cijepiti, mnoge od tih bolesti i s njima povezane epidemije mogle bi se vratiti.</seg>
</tuv>
</tu>
<tu tuid="100">
<prop type="lengthRatio">0.9125</prop>
<tuv xml:lang="en">
<seg>It can cause severe spasms of cough and usually lasts three to six weeks.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac može izazvati teške napadaje kašlja i obično traje tri do šest tjedana.</seg>
</tuv>
</tu>
<tu tuid="101">
<prop type="lengthRatio">1.0194174757281553</prop>
<tuv xml:lang="en">
<seg>Vaccines are used in hundreds of millions of people worldwide each year to protect from serious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stotine milijuna ljudi diljem svijeta svake se godine cijepi kako bi se zaštitili od ozbiljnih bolesti.</seg>
</tuv>
</tu>
<tu tuid="102">
<prop type="lengthRatio">1.0379746835443038</prop>
<tuv xml:lang="en">
<seg>However, since October 2016 a resurgence of measles has been observed in the EU/EEA, with outbreaks in several countries (2), due to a decline in vaccination rates.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, od listopada 2016. uočena je ponovna pojava ospica u EU-u/EGP-u uz epidemije u nekoliko zemalja (2), što je povezano sa smanjenom stopom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="103">
<prop type="lengthRatio">0.9210526315789473</prop>
<tuv xml:lang="en">
<seg>About 20% of infants will have redness and pain at the injection site.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Oko 20 % djece imat će crvenilo i osjećati bol na mjestu primjene injekcije.</seg>
</tuv>
</tu>
<tu tuid="104">
<prop type="lengthRatio">1.096774193548387</prop>
<tuv xml:lang="en">
<seg>For example, during 2018 about 86% of infants worldwide received three doses of the vaccine that protects them against diphtheria, tetanus and pertussis (DTP), and 85% of infants around the world received three doses of polio vaccine (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, tijekom 2018. oko 86 % male djece diljem svijeta primilo je tri doze cjepiva za zaštitu od difterije, tetanusa i hripavca (cjepivo DTP), a 85 % djece primilo je tri doze cjepiva protiv dječje paralize (1).</seg>
</tuv>
</tu>
<tu tuid="105">
<prop type="lengthRatio">1.12</prop>
<tuv xml:lang="en">
<seg>Vaccination against pertussis is part of national immunisation programmes in the EU.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje protiv hripavca dio je nacionalnih programa cijepljenja u EU-u.</seg>
</tuv>
</tu>
<tu tuid="106">
<prop type="lengthRatio">1.0296296296296297</prop>
<tuv xml:lang="en">
<seg>Many infectious diseases are very rare today thanks to vaccination, so the negative consequences of these diseases are sometimes forgotten.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju mnoge su zarazne bolesti danas vrlo rijetke, tako da se ponekad zaboravljaju negativne posljedice tih bolesti.</seg>
</tuv>
</tu>
<tu tuid="107">
<prop type="lengthRatio">0.9318181818181818</prop>
<tuv xml:lang="en">
<seg>Unlike a treatment given to cure an illness, vaccines are usually given to healthy people to prevent them from getting ill.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za razliku od terapije koja se daje za liječenje bolesti, cjepiva se obično daju zdravim ljudima kako bi ih se zaštitilo od bolesti.</seg>
</tuv>
</tu>
<tu tuid="108">
<prop type="lengthRatio">1.0303030303030303</prop>
<tuv xml:lang="en">
<seg>Complications can include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije mogu uključivati upalu pluća, encefalopatiju (bolest mozga), konvulzije pa čak i smrt.</seg>
</tuv>
</tu>
<tu tuid="109">
<prop type="lengthRatio">0.96</prop>
<tuv xml:lang="en">
<seg>Measles can be serious or even life-threatening.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice mogu biti ozbiljne ili čak opasne po život.</seg>
</tuv>
</tu>
<tu tuid="110">
<prop type="lengthRatio">1.1590909090909092</prop>
<tuv xml:lang="en">
<seg>The only protection against measles is vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina zaštita protiv ospica je cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="111">
<prop type="lengthRatio">1.3571428571428572</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ono je sigurno i učinkovito.</seg>
</tuv>
</tu>
<tu tuid="112">
<prop type="lengthRatio">1.2833333333333334</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR štiti od ospica, zaušnjaka i rubeole (crljenca).</seg>
</tuv>
</tu>
<tu tuid="113">
<prop type="lengthRatio">0.6923076923076923</prop>
<tuv xml:lang="en">
<seg>For more information, see measles factsheet .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za dodatne informacije pogledajte informativni sažetak o hripavcu</seg>
</tuv>
</tu>
<tu tuid="114">
<prop type="lengthRatio">0.7230769230769231</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za dodatne informacije pogledajte informativni sažetak o ospicama</seg>
</tuv>
</tu>
<tu tuid="115">
<prop type="lengthRatio">0.9841269841269841</prop>
<tuv xml:lang="en">
<seg>Pertussis (whooping cough) is a disease affecting the airways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac (magareći kašalj) je bolest koja zahvaća dišne puteve.</seg>
</tuv>
</tu>
<tu tuid="116">
<prop type="lengthRatio">1.5555555555555556</prop>
<tuv xml:lang="en">
<seg>This protects children from whooping cough, while it only causes minor side effects.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Time se djeca štite od hripavca, a nuspojave su blage.</seg>
</tuv>
</tu>
<tu tuid="117">
<prop type="lengthRatio">1.8235294117647058</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Primjer: hripavac</seg>
</tuv>
</tu>
<tu tuid="118">
<prop type="lengthRatio">1.224770642201835</prop>
<tuv xml:lang="en">
<seg>Factors driving such differences may include the disease's burden, prevalence of the disease and trends in different countries, the resources and structures of healthcare systems, political and cultural factors, as well as the resilience of the vaccination programme.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Razlozi za te razlike mogu uključivati teret bolesti, njenu pojavnost i trendove u različitim zemljama, resurse i strukture zdravstvenih sustava, političke i kulturološke čimbenike kao i otpornost programa cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="119">
<prop type="lengthRatio">1.0845588235294117</prop>
<tuv xml:lang="en">
<seg>These may include the age and population to be vaccinated (for example, all children of a certain age or only those in a risk group), the exact type of vaccine (e.g. some ingredients may differ), the number and timing of doses, and whether a vaccine is given alone or in combination with others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Te se razlike mogu odnositi na dob i skupine koje treba cijepiti (na primjer, sva djeca ili samo ona iz rizične skupine), određeni tip cjepiva (neki se sastojci mogu razlikovati), broj i raspored doza te primjenjuje li se cjepivo samo ili u kombinaciji s drugim cjepivima.</seg>
</tuv>
</tu>
<tu tuid="120">
<prop type="lengthRatio">0.9612903225806452</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country is responsible for its own national public health policy, including its national immunisation programme and vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka država EU-a / EGP-a odgovorna je za svoju nacionalnu politiku javnog zdravstva, uključujući za nacionalni program cijepljenja i raspored cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="121">
<prop type="lengthRatio">1.0555555555555556</prop>
<tuv xml:lang="en">
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postoje neke razlike u organizaciji rasporeda cijepljenja među zemljama, koji su slični, ali ne i posve isti u različitim državama EU-a / EGP-a.</seg>
</tuv>
</tu>
<tu tuid="122">
<prop type="lengthRatio">1.0327868852459017</prop>
<tuv xml:lang="en">
<seg>The same level of protection is ensured in each EU/EEA country.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ista razina zaštite osigurana je u svim zemljama EU-a / EGP-a</seg>
</tuv>
</tu>
<tu tuid="123">
<prop type="lengthRatio">1.1219512195121952</prop>
<tuv xml:lang="en">
<seg>The childhood vaccination schedules in all EU/EEA countries include the vaccination against:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rasporedi cijepljenja djece u svim državama EU-a / EGP-a uključuju cjepiva protiv:</seg>
</tuv>
</tu>
<tu tuid="124">
<prop type="lengthRatio">0.9130434782608695</prop>
<tuv xml:lang="en">
<seg>Vaccines in the national schedules are given in the appropriate timeframes to ensure adequate protection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za osiguranje odgovarajuće zaštite, cjepiva se u nacionalnim rasporedima daju u odgovarajućim vremenskim razmacima.</seg>
</tuv>
</tu>
<tu tuid="125">
<prop type="lengthRatio">0.65</prop>
<tuv xml:lang="en">
<seg>The differences between vaccination schedules do not mean that some are better than others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Razlike među rasporedima cijepljenja ne znače da su neki bolji od drugih, samo se uzimaju u obzir različite okolnosti i zdravstvene sustave.</seg>
</tuv>
</tu>
<tu tuid="126">
<prop type="lengthRatio">1.008849557522124</prop>
<tuv xml:lang="en">
<seg>Information on the national vaccination schedules in EU/EEA countries can be found in the ECDC Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Podatci o nacionalnim rasporedima cijepljenja u državama EU-a / EGP-a nalaze se u ECDC-ovom rasporedu cijepljenja</seg>
</tuv>
</tu>
<tu tuid="127">
<prop type="lengthRatio">1.0434782608695652</prop>
<tuv xml:lang="en">
<seg>They can still catch up.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To se može nadoknaditi.</seg>
</tuv>
</tu>
<tu tuid="128">
<prop type="lengthRatio">1.0113636363636365</prop>
<tuv xml:lang="en">
<seg>Some people may have missed a vaccination or did not get the recommended number of doses.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neki su ljudi možda propustili jedno cijepljenje ili nisu primili preporučeni broj doza.</seg>
</tuv>
</tu>
<tu tuid="129">
<prop type="lengthRatio">0.7017543859649122</prop>
<tuv xml:lang="en">
<seg>Most vaccines provide lifelong immunity.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina cjepiva osigurava imunitet tijekom cijelog života.</seg>
</tuv>
</tu>
<tu tuid="130">
<prop type="lengthRatio">1.2374100719424461</prop>
<tuv xml:lang="en">
<seg>If a person does not know if they have been vaccinated against a certain disease they can usually get an extra dose without increasing the risk of serious side effects (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako netko ne zna je li cijepljen protiv određene bolesti, obično može primiti dodatnu dozu bez povećanog rizika od ozbiljnih nuspojava (1).</seg>
</tuv>
</tu>
<tu tuid="131">
<prop type="lengthRatio">0.8532110091743119</prop>
<tuv xml:lang="en">
<seg>However, some vaccines provide immunity that decreases over time, known as ‘waning immunity'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, neka cjepiva pružaju imunitet koji se s vremenom smanjuje, poznat pod nazivom „imunitet koji slabi".</seg>
</tuv>
</tu>
<tu tuid="132">
<prop type="lengthRatio">0.9932885906040269</prop>
<tuv xml:lang="en">
<seg>Everyone should check if they have had the nationally recommended vaccinations, and consult a medical professional in case any catch-ups are needed.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko bi trebao provjeriti je li primio cjepiva preporučena na nacionalnoj razini i savjetovati se s liječnikom ako su mu potrebna naknadna cjepiva.</seg>
</tuv>
</tu>
<tu tuid="133">
<prop type="lengthRatio">0.9416058394160584</prop>
<tuv xml:lang="en">
<seg>For some diseases, such as varicella (chickenpox) and rubella, it is also possible to do a test to check if the person is immune.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih bolesti, poput vodenih kozica (varicelle) i rubeole postoji test kojim se može provjeriti je li osoba na njih razvila imunitet.</seg>
</tuv>
</tu>
<tu tuid="134">
<prop type="lengthRatio">0.8918918918918919</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination and boosters</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Naknadna cijepljenja i docjepljivanje</seg>
</tuv>
</tu>
<tu tuid="135">
<prop type="lengthRatio">1.1326530612244898</prop>
<tuv xml:lang="en">
<seg>This may involve looking at vaccination records or the vaccination schedules in place when the person was born.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To može podrazumijevati provjeru knjižica ili rasporeda cijepljenja u mjestu gdje je osoba rođena.</seg>
</tuv>
</tu>
<tu tuid="136">
<prop type="lengthRatio">0.9942857142857143</prop>
<tuv xml:lang="en">
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neke zemlje preporučuju docjepljivanje u redovnim razmacima tijekom puberteta i u odrasloj dobi kako bi se imunitet dulje vrijeme održao protiv bolesti kao što su, na primjer:</seg>
</tuv>
</tu>
<tu tuid="137">
<prop type="lengthRatio">1.011070110701107</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, zbog sve veće pojavnosti ospica među tinejdžerima i mlađim odraslim osobama u brojim zemljama EU-a / EGP-a dostupni su programi naknadnog cijepljenja za osobe koje nisu cijepljene protiv ospica u djetinjstvu ili im to cjepivo u djetinjstvu nije bilo dostupno.</seg>
</tuv>
</tu>
<tu tuid="138">
<prop type="lengthRatio">0.9594594594594594</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination programmes for specific diseases may be organised.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za određene bolesti moguće je organizirati programe naknadnog cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="139">
<prop type="lengthRatio">0.91</prop>
<tuv xml:lang="en">
<seg>For example, tetanus can be encountered due to common injuries, including dog or cat bites.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, tetanus se može razviti zbog uobičajenih ozljeda, uključujući od ugriza pasa ili mačaka.</seg>
</tuv>
</tu>
<tu tuid="140">
<prop type="lengthRatio">1.2666666666666666</prop>
<tuv xml:lang="en">
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To se zove „kolektivni imunitet" (ili „imunitet zajednice").</seg>
</tuv>
</tu>
<tu tuid="141">
<prop type="lengthRatio">1.1300448430493273</prop>
<tuv xml:lang="en">
<seg>For example, to ensure community immunity against measles, public health authorities recommend that 95% of the population are vaccinated with two doses of the vaccine against measles (the MMR vaccine, which protects against measles, mumps and rubella).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, da bi se u zajednici osigurala imunost na ospice, zavodi za javno zdravstvo preporučuju da se 95 % stanovništva cijepi s dvije doze cjepiva protiv ospica (cjepivom MMR koje štiti od ospica, zaušnjaka i rubeole).</seg>
</tuv>
</tu>
<tu tuid="142">
<prop type="lengthRatio">0.9755244755244755</prop>
<tuv xml:lang="en">
<seg>Furthermore, immunisation programmes help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nadalje, programi cijepljenja pomažu u smanjenju socijalnih, psiholoških i financijskih tereta od bolesti na pojedince i državu, uključujući manji pritisak na sustave zdravstva i socijalne skrbi te omogućavajući ljudima da se bave produktivnim aktivnostima kao što su obrazovanje i rad.</seg>
</tuv>
</tu>
<tu tuid="143">
<prop type="lengthRatio">1.0165289256198347</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases, reducing the risk of diseases spreading among family members, school mates or colleagues, friends, neighbours and other people in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se štiti i cijepljene osobe i osobe iz njihova okruženja koje su podložne bolestima, čime se smanjuje rizik od širenja bolesti među članovima obitelji, učenicima ili kolegama, prijateljima, susjedima i drugim ljudima u zajednici.</seg>
</tuv>
</tu>
<tu tuid="144">
<prop type="lengthRatio">1.0092592592592593</prop>
<tuv xml:lang="en">
<seg>It means that people who cannot be vaccinated, for instance because they are too young or allergic to vaccine components, benefit from others being vaccinated, because the disease cannot easily spread in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To znači da su osobe koje se ne mogu cijepiti, na primjer zato što su premlade ili alergične na sastojke cjepiva, djelomično zaštićene jer su ljudi oko njih cijepljeni te se bolest ne može lako proširiti u zajednici.</seg>
</tuv>
</tu>
<tu tuid="145">
<prop type="lengthRatio">1.0066666666666666</prop>
<tuv xml:lang="en">
<seg>These include babies, children, the elderly, people with weak immune systems, cancer patients, and people who cannot be vaccinated for medical reasons.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Podložne osobe su bebe, djeca, stariji ljudi, osobe sa slabim imunitetom, oboljeli od raka i osobe koje se zbog medicinskih razloga ne smiju cijepiti.</seg>
</tuv>
</tu>
<tu tuid="146">
<prop type="lengthRatio">1.1367521367521367</prop>
<tuv xml:lang="en">
<seg>When enough people in a population are immune to an infectious disease, the disease is then unlikely to spread from person to person.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada je dovoljan broj osoba imun na zarazne bolesti, mala je vjerojatnost da će se bolest prenositi s osobe na osobu.</seg>
</tuv>
</tu>
<tu tuid="147">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>In this way, vaccines indirectly protect others who are vulnerable to disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na taj se način cjepivom neizravno štiti i druge osobe podložne bolesti.</seg>
</tuv>
</tu>
<tu tuid="148">
<prop type="lengthRatio">1.2857142857142858</prop>
<tuv xml:lang="en">
<seg>Vaccination is the only way to ensure direct protection against tetanus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Izravna zaštita od tetanusa moguća je samo cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="149">
<prop type="lengthRatio">1.103448275862069</prop>
<tuv xml:lang="en">
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kolektivni imunitet postiže se kad je dovoljan broj stanovnika imun na zarazne bolesti.</seg>
</tuv>
</tu>
<tu tuid="150">
<prop type="lengthRatio">0.9186046511627907</prop>
<tuv xml:lang="en">
<seg>However, people cannot rely on community immunity for some infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, kod nekih zaraznih bolesti ljudi se ne mogu oslanjati na kolektivni imunitet.</seg>
</tuv>
</tu>
<tu tuid="151">
<prop type="lengthRatio">1.0625</prop>
<tuv xml:lang="en">
<seg>When looking at health-related information, it can be difficult to judge the quality and accuracy of information found.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pri razmatranju zdravstvenih informacija može biti teško procijeniti kvalitetu i točnost pronađenih informacija.</seg>
</tuv>
</tu>
<tu tuid="152">
<prop type="lengthRatio">0.86</prop>
<tuv xml:lang="en">
<seg>Official websites from EU and EEA countries</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Službena mrežna mjesta država članica EU-a i EGP-a</seg>
</tuv>
</tu>
<tu tuid="153">
<prop type="lengthRatio">1.2027027027027026</prop>
<tuv xml:lang="en">
<seg>People may wonder where to find accurate information, who is behind the development of the information they find, and also if the information is supported by scientific evidence.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu se pitati gdje pronaći točne informacije, tko stoji iza informacija koje pronađu te jesu li te informacije potkrijepljene znanstvenim dokazima.</seg>
</tuv>
</tu>
<tu tuid="154">
<prop type="lengthRatio">1.0125786163522013</prop>
<tuv xml:lang="en">
<seg>The Vaccine Safety Net (VSN) is a global network of websites, established by the World Health Organization, that provides reliable information on vaccine safety.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Vaccine Safety Net (VSN) globalna je mreža portala koju je uspostavila Svjetska zdravstvena organizacija i koja nudi pouzdane informacije o sigurnosti cjepiva.</seg>
</tuv>
</tu>
<tu tuid="155">
<prop type="lengthRatio">0.8514851485148515</prop>
<tuv xml:lang="en">
<seg>Below are links to official websites with information on vaccination from public health organisations of the European Union (EU) and European Economic Area (EEA) countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nastavku su poveznice na službena mrežna mjesta s informacijama o cijepljenju koje su izradile organizacije javnog zdravstva država članica Europske unije (EU) i Europskog gospodarskog prostora (EGP).</seg>
</tuv>
</tu>
<tu tuid="156">
<prop type="lengthRatio">1.0738636363636365</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level, in order to facilitate access to trusted sources of information, such as:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U ovoj rubrici pronaći ćete poveznice na mrežna mjesta drugih nacionalnih i međunarodnih zdravstvenih organizacija, koje će vam olakšati pristup pouzdanim izvorima informacija.</seg>
</tuv>
</tu>
<tu tuid="157">
<prop type="lengthRatio">0.35023041474654376</prop>
<tuv xml:lang="en">
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako želite više informacija o toj mreži, posjetite: https://vaccinesafetynet.org . Informacije o članicama mreže VSN i poveznice na njihova mrežna mjesta dostupne su ovdje: https://www.vaccinesafetynet.org/vsn/network</seg>
</tuv>
</tu>
<tu tuid="158">
<prop type="lengthRatio">1.096</prop>
<tuv xml:lang="en">
<seg>With all the information that is available on the internet and circulating on social media on vaccination, people may sometimes get lost.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ljudi se ponekad mogu izgubiti u mnoštvu informacija o cijepljenju koje su dostupne na internetu i kolaju društvenim mrežama.</seg>
</tuv>
</tu>
<tu tuid="159">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Thousands of volunteers</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tisuće dobrovoljaca</seg>
</tuv>
</tu>
<tu tuid="160">
<prop type="lengthRatio">0.8831168831168831</prop>
<tuv xml:lang="en">
<seg>its ingredients, including its inactive ingredients or ‘excipients';</seg>
</tuv>
<tuv xml:lang="hr">
<seg>njegovi sastojci, uključujući njegove neaktivne sastojke ili „pomoćne tvari";</seg>
</tuv>
</tu>
<tu tuid="161">
<prop type="lengthRatio">0.7794117647058824</prop>
<tuv xml:lang="en">
<seg>This involves tests in the laboratory and in animals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pod tim se podrazumijeva testiranje u laboratoriju i na životinjama.</seg>
</tuv>
</tu>
<tu tuid="162">
<prop type="lengthRatio">0.6875</prop>
<tuv xml:lang="en">
<seg>its purity;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>njegova čistoća;</seg>
</tuv>
</tu>
<tu tuid="163">
<prop type="lengthRatio">1.0869565217391304</prop>
<tuv xml:lang="en">
<seg>What is the optimal dose?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koja je optimalna doza?</seg>
</tuv>
</tu>
<tu tuid="164">
<prop type="lengthRatio">0.9090909090909091</prop>
<tuv xml:lang="en">
<seg>Is the vaccine safe?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Je li cjepivo sigurno?</seg>
</tuv>
</tu>
<tu tuid="165">
<prop type="lengthRatio">0.8421052631578947</prop>
<tuv xml:lang="en">
<seg>This programme has to follow the procedures and protocols set by the regulators:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U sklopu programa moraju se slijediti postupci i protokoli koje je utvrdilo regulatorno tijelo:</seg>
</tuv>
</tu>
<tu tuid="166">
<prop type="lengthRatio">0.967391304347826</prop>
<tuv xml:lang="en">
<seg>These include the European Medicines Agency and other regulators in the EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ta su tijela Europska agencija za lijekove i druga regulatorna tijela u državama EU-a/EGP-a.</seg>
</tuv>
</tu>
<tu tuid="167">
<prop type="lengthRatio">1.2777777777777777</prop>
<tuv xml:lang="en">
<seg>how it is manufactured.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>način proizvodnje.</seg>
</tuv>
</tu>
<tu tuid="168">
<prop type="lengthRatio">0.8888888888888888</prop>
<tuv xml:lang="en">
<seg>Testing includes checking the vaccine's quality:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ispitivanjem je obuhvaćena provjera kvalitete cjepiva:</seg>
</tuv>
</tu>
<tu tuid="169">
<prop type="lengthRatio">1.46</prop>
<tuv xml:lang="en">
<seg>How are the immune systems of the participants responding to the vaccine?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako imunosni sustav sudionika reagira na cjepivo?</seg>
</tuv>
</tu>
<tu tuid="170">
<prop type="lengthRatio">0.7947019867549668</prop>
<tuv xml:lang="en">
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Subjekt koji razvija cjepivo provodi u sklopu testiranja tri faze kliničkog ispitivanja cjepiva pri čemu je u svakoj fazi uključen sve veći broj ljudi.</seg>
</tuv>
</tu>
<tu tuid="171">
<prop type="lengthRatio">1.225</prop>
<tuv xml:lang="en">
<seg>What are the most common short-term side effects?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su najčešće kratkotrajne nuspojave?</seg>
</tuv>
</tu>
<tu tuid="172">
<prop type="lengthRatio">1.0650887573964498</prop>
<tuv xml:lang="en">
<seg>At the end of the testing programme, the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘marketing authorisation' application.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon programa testiranja subjekt koji razvija cjepivo podnosi rezultate regulatornom tijelu za lijekove u Europi kao dio zahtjeva za „odobrenje za stavljanje u promet".</seg>
</tuv>
</tu>
<tu tuid="173">
<prop type="lengthRatio">0.8783068783068783</prop>
<tuv xml:lang="en">
<seg>This is followed by a clinical testing programme in humans, which can take around ten years from initial concept to authorisation and must adhere to strict standards.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Potom slijedi klinički program testiranja na ljudima, koji može trajati oko 10 godina i započinje s inicijalnim konceptom, a završava s odobrenjem, te mora biti u skladu sa strogim normama.</seg>
</tuv>
</tu>
<tu tuid="174">
<prop type="lengthRatio">0.765</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije nego što se cjepivo može odobriti u EU-u, ono mora biti podvrgnuto strogom ispitivanju od strane subjekta koji razvija cjepivo, a nakon toga znanstvenoj procjeni koju provode regulatorna tijela.</seg>
</tuv>
</tu>
<tu tuid="175">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The companies are required to conduct stringent testing, for which the acceptance criteria are pre-defined by the authorities, on each batch of vaccine released onto the EU market.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Od tvrtki se zahtijeva da provedu stroga ispitivanja čije su kriterije prihvatljivosti unaprijed definirala nadležna tijela, za svaku seriju cjepiva stavljenu u promet unutar EU-a.</seg>
</tuv>
</tu>
<tu tuid="176">
<prop type="lengthRatio">0.8870967741935484</prop>
<tuv xml:lang="en">
<seg>Then the vaccine developer tests the vaccine's effects.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon toga subjekt koji razvija cjepivo testira njegov učinak.</seg>
</tuv>
</tu>
<tu tuid="177">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu provoditi i ispitivanja kako bi bila sigurna da su serije cjepiva stavljene u promet odgovarajuće kvalitete te da su ispravno proizvedene.</seg>
</tuv>
</tu>
<tu tuid="178">
<prop type="lengthRatio">0.952054794520548</prop>
<tuv xml:lang="en">
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Regulatorna tijela za lijekove provode provjere kako bi osigurala da su informacije o cjepivu koje je naveo subjekt koji razvija cjepivo pouzdane.</seg>
</tuv>
</tu>
<tu tuid="179">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Regulatorna tijela mogu tek onda odobriti cjepivo ako je znanstvenom procjenom rezultata ispitivanja utvrđeno da koristi cjepiva nadmašuju njegove rizike .</seg>
</tuv>
</tu>
<tu tuid="180">
<prop type="lengthRatio">1.4074074074074074</prop>
<tuv xml:lang="en">
<seg>What are the most common side effects?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su najčešće nuspojave?</seg>
</tuv>
</tu>
<tu tuid="181">
<prop type="lengthRatio">1.4761904761904763</prop>
<tuv xml:lang="en">
<seg>Are there serious side effects?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djelotvornost cjepiva</seg>
</tuv>
</tu>
<tu tuid="182">
<prop type="lengthRatio">0.543859649122807</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Praćenje sigurnosti cjepiva i izvješćivanje o nuspojavama</seg>
</tuv>
</tu>
<tu tuid="183">
<prop type="lengthRatio">1.0204081632653061</prop>
<tuv xml:lang="en">
<seg>European Centre for Disease Prevention and Control</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europski centar za sprečavanje i kontrolu bolesti</seg>
</tuv>
</tu>
<tu tuid="184">
<prop type="lengthRatio">0.8620689655172413</prop>
<tuv xml:lang="en">
<seg>European Medicines Agency</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska agencija za lijekove</seg>
</tuv>
</tu>
<tu tuid="185">
<prop type="lengthRatio">1.3865546218487395</prop>
<tuv xml:lang="en">
<seg>It is alone responsible for drawing up proposals for new European legislation, and it implements the decisions of the European Parliament and the Council of the EU .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina je nadležna za pripremu prijedloga novog zakonodavstva EU-a te provodi odluke Europskog parlamenta i Vijeća EU-a</seg>
</tuv>
</tu>
<tu tuid="186">
<prop type="lengthRatio">0.8767123287671232</prop>
<tuv xml:lang="en">
<seg>These experts carry out the work of EMA's scientific committees.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ti stručnjaci obavljaju djelatnosti u sklopu EMA-inih znanstvenih odbora.</seg>
</tuv>
</tu>
<tu tuid="187">
<prop type="lengthRatio">1.2542372881355932</prop>
<tuv xml:lang="en">
<seg>The European Commission is the EU's politically independent executive arm.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska komisija politički je neovisna izvršna grana EU-a.</seg>
</tuv>
</tu>
<tu tuid="188">
<prop type="lengthRatio">0.9514563106796117</prop>
<tuv xml:lang="en">
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA je organizacija čije aktivnosti obuhvaćaju mrežu od više tisuća stručnjaka iz svih dijelova Europe.</seg>
</tuv>
</tu>
<tu tuid="189">
<prop type="lengthRatio">1.064516129032258</prop>
<tuv xml:lang="en">
<seg>(1) The European Commission, ECDC and EMA have mechanisms in place in order to ensure impartiality.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(1) Europska komisija, ECDC i EMA imaju uspostavljene mehanizme za osiguranje nepristranosti.</seg>
</tuv>
</tu>
<tu tuid="190">
<prop type="lengthRatio">0.8469387755102041</prop>
<tuv xml:lang="en">
<seg>The Commission is divided into departments that develop policies in specific areas.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>. Komisija je organizirana na temelju glavnih uprava koje razvijaju politiku za određena područja.</seg>
</tuv>
</tu>
<tu tuid="191">
<prop type="lengthRatio">0.898876404494382</prop>
<tuv xml:lang="en">
<seg>EMA and its scientific committees examine all available data and assess their benefits and risks before they are approved and while they are marketed in the EU.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA i njeni znanstveni odbori analiziraju sve dostupne podatke te procjenjuju njihove koristi i rizike prije izdavanja odobrenja kao i tijekom njihova stavljanja na tržište EU-a.</seg>
</tuv>
</tu>
<tu tuid="192">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>This is to ensure that staff and experts do not, in the performance of their duties, deal with matters in which they may, directly or indirectly, have a personal interest that could impair their independence.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Time se osigurava da osoblje i stručnjaci tijekom izvršavanja svojih dužnosti ne rade na predmetima u kojima bi, izravno ili neizravno, mogli imati osobni interes koji bi mogao ugroziti njihovu nepristranost.</seg>
</tuv>
</tu>
<tu tuid="193">
<prop type="lengthRatio">0.9053254437869822</prop>
<tuv xml:lang="en">
<seg>Staff and experts are required to declare any personal interest or any interest in any business or organisation that could compromise their impartiality.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osoblje i stručnjaci dužni su prijaviti bilo kakav osobni interes ili interes u bilo kakvom poslovanju odnosno organizaciji koji bi mogao ugroziti njihovu nepristranost.</seg>
</tuv>
</tu>
<tu tuid="194">
<prop type="lengthRatio">0.9043478260869565</prop>
<tuv xml:lang="en">
<seg>Communication and scientific experts in these organisations are involved in developing the contents (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Znanstveni stručnjaci, kao i oni za komunikaciju, u spomenutim organizacijama uključeni su u pripremu sadržaja (1).</seg>
</tuv>
</tu>
<tu tuid="195">
<prop type="lengthRatio">0.9661016949152542</prop>
<tuv xml:lang="en">
<seg>EMA ensures the efficacy, quality and safety of vaccines.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA osigurava djelotvornost, kvalitetu i sigurnost cjepiva.</seg>
</tuv>
</tu>
<tu tuid="196">
<prop type="lengthRatio">1.1337579617834395</prop>
<tuv xml:lang="en">
<seg>It also provides an overview of the mechanisms in place in the European Union (EU) to ensure that available vaccines conform to the highest standards of safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Također sadrži pregled mehanizama u Europskoj uniji (EU) kojima se osigurava usklađenost dostupnih cjepiva s najvišim standardima sigurnosti i učinkovitosti.</seg>
</tuv>
</tu>
<tu tuid="197">
<prop type="lengthRatio">0.9318181818181818</prop>
<tuv xml:lang="en">
<seg>EMA works closely with European and international partners and shares information on vaccines and good regulatory practice.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA blisko surađuje s europskim i međunarodnim partnerima te razmjenjuje informacije o cjepivima kao i pozitivnu regulatornu praksu.</seg>
</tuv>
</tu>
<tu tuid="198">
<prop type="lengthRatio">0.9115646258503401</prop>
<tuv xml:lang="en">
<seg>ECDC also maintains the Vaccine Scheduler , an online, interactive platform showing the vaccination schedules of all EU Member States.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ECDC također održava raspored cijepljenja , interaktivnu internetsku platformu koja prikazuje rasporede cijepljenja u svim državama članicama EU-a.</seg>
</tuv>
</tu>
<tu tuid="199">
<prop type="lengthRatio">1.048951048951049</prop>
<tuv xml:lang="en">
<seg>Representatives from EU and EEA countries' public health organisations were consulted for finalising the website's contents and its language versions.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Predstavnici javnog zdravstva iz država EU-a i EGP-a konzultirani su u završnoj fazi pripreme sadržaja za mrežno mjesto i oko jezičnih verzija.</seg>
</tuv>
</tu>
<tu tuid="200">
<prop type="lengthRatio">1.10989010989011</prop>
<tuv xml:lang="en">
<seg>ECDC is an EU scientific agency aimed at strengthening Europe's defences against infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ECDC je znanstvena agencija EU-a čiji je cilj jačati obranu protiv zaraznih bolesti u EU-u.</seg>
</tuv>
</tu>
<tu tuid="201">
<prop type="lengthRatio">0.9532374100719424</prop>
<tuv xml:lang="en">
<seg>The core functions cover a wide spectrum of activities: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osnovna djelatnost agencije obuhvaća razne aktivnosti: nadzor, epidemiološku inteligenciju, odgovore, znanstvene savjete, mikrobiologiju, pripravnost, obuku u području javnog zdravstva, međunarodne odnose, komunikaciju u području zdravstva i znanstveni časopis Eurosurveillance.</seg>
</tuv>
</tu>
<tu tuid="202">
<prop type="lengthRatio">1.0382978723404255</prop>
<tuv xml:lang="en">
<seg>This website was developed by the European Centre for Disease Prevention and Control (ECDC), in partnership with the European Commission, specifically, its Department on Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mrežno mjesto razvio je Europski centar za sprečavanje i kontrolu bolesti (ECDC) u partnerstvu s Europskom komisijom, točnije s njenom Glavnom upravom za zdravlje i sigurnost hrane (DG SANTE) te s Europskom agencijom za lijekove (EMA).</seg>
</tuv>
</tu>
<tu tuid="203">
<prop type="lengthRatio">1.2211538461538463</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination in general.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osnovna je svrha ovog mrežnog mjesta pružiti točne, objektivne i ažurne podatke o cjepivu i cijepljenju.</seg>
</tuv>
</tu>
<tu tuid="204">
<prop type="lengthRatio">1.1595092024539877</prop>
<tuv xml:lang="en">
<seg>The European Medicines Agency (EMA) is a decentralized agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska agencija za lijekove (EMA) decentralizirana je agencija Europske unije (EU) nadležna za znanstvenu procjenu, nadzor i praćenje sigurnosti lijekova u EU-u.</seg>
</tuv>
</tu>
<tu tuid="205">
<prop type="lengthRatio">0.9820359281437125</prop>
<tuv xml:lang="en">
<seg>One of the departments is DG for Health and Food Safety , responsible for EU policy on food safety and health and for monitoring the implementation of related laws.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedna od njih je i Glavna uprava za zdravlje i sigurnost hrane , nadležna za politiku EU-a u području sigurnosti hrane te za praćenje provedbe povezanog zakonodavstva.</seg>
</tuv>
</tu>
<tu tuid="206">
<prop type="lengthRatio">0.8985507246376812</prop>
<tuv xml:lang="en">
<seg>In the area of vaccine-preventable diseases, ECDC provides regular surveillance data, e.g. the number of confirmed cases, and scientific advice on vaccines, monitors disease outbreaks and develops materials to support communication on immunisation.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U području bolesti koje se mogu spriječiti cijepljenjem, ECDC redovno osigurava podatke proistekle iz nadzora, kao što je broj potvrđenih slučajeva te znanstvene savjete o cjepivima, prati izbijanja epidemija i razvija materijale kojima se podržava komunikacija o cijepljenju.</seg>
</tuv>
</tu>
<tu tuid="207">
<prop type="lengthRatio">0.7647058823529411</prop>
<tuv xml:lang="en">
<seg>Read more: https://ec.europa.eu/health/vaccination/overview_en and https://ec.europa.eu/info/departments/health-and-food-safety_en</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija nalazi se na sljedećim poveznicama: https://ec.europa.eu/health/vaccination/overview_en i https://ec.europa.eu/info/departments/health-and-food-safety_hr</seg>
</tuv>
</tu>
<tu tuid="208">
<prop type="lengthRatio">0.8088235294117647</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ema.europa.eu /</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija nalazi se na poveznici: https://www.ema.europa.eu /</seg>
</tuv>
</tu>
<tu tuid="209">
<prop type="lengthRatio">0.8088235294117647</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ecdc.europa.eu/</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija nalazi se na poveznici: https://www.ecdc.europa.eu/</seg>
</tuv>
</tu>
<tu tuid="210">
<prop type="lengthRatio">0.84375</prop>
<tuv xml:lang="en">
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>. Cilj je inicijative odgovoriti na oklijevanje s cijepljenjem, poboljšati koordinaciju u nabavi cjepiva, podržati istraživanje i razvoj te ojačati suradnju unutar EU-a u pogledu bolesti koje se mogu spriječiti cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="211">
<prop type="lengthRatio">1.0872093023255813</prop>
<tuv xml:lang="en">
<seg>It is an initiative of the European Union and was developed following the Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases adopted in December 2018.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ova je inicijativa Europske unije pokrenuta na temelju Preporuke Vijeća o jačoj suradnji u suzbijanju bolesti koje se mogu spriječiti cijepljenjem usvojene u prosincu 2018.</seg>
</tuv>
</tu>
<tu tuid="212">
<prop type="lengthRatio">0.8823529411764706</prop>
<tuv xml:lang="en">
<seg>To improve vaccination uptake, the Council adopted a Recommendation to strengthen the EU cooperation on vaccine-preventable diseases in December 2018.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>S ciljem postizanja veće procijepljenosti, Vijeće je u prosincu 2018. usvojilo Preporuke o jačoj suradnji u EU-u u suzbijanju bolesti koje se mogu spriječiti cijepljenjem</seg>
</tuv>
</tu>
<tu tuid="213">
<prop type="lengthRatio">0.47058823529411764</prop>
<tuv xml:lang="en">
<seg>About us</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska komisija</seg>
</tuv>
</tu>
<tu tuid="214">
<prop type="lengthRatio">1.0379746835443038</prop>
<tuv xml:lang="en">
<seg>It is also spread via secretions on hands, tissues and surfaces that people touch.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Također se širi putem sekreta preko ruku, tkiva i površina koje ljudi dodiruju.</seg>
</tuv>
</tu>
<tu tuid="215">
<prop type="lengthRatio">0.945054945054945</prop>
<tuv xml:lang="en">
<seg>Patients are advised to seek medical advice if their condition continues to get worse.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bolesnicima se savjetuje da potraže liječnički savjet ako im se stanje nastavi pogoršavati.</seg>
</tuv>
</tu>
<tu tuid="216">
<prop type="lengthRatio">1.35</prop>
<tuv xml:lang="en">
<seg>Children are infected slightly more often than adults.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djeca se zaraze nešto češće od odraslih.</seg>
</tuv>
</tu>
<tu tuid="217">
<prop type="lengthRatio">0.8352941176470589</prop>
<tuv xml:lang="en">
<seg>The 2009 A(H1N1)pdm09 influenza pandemic accounted for 123 000 to 203 000 deaths worldwide and a significant global socio-economic burden (3).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pandemija gripe 2009 A(H1N1)pdm09 za posljedicu je imala između 123 000 do 203 000 smrtnih slučajeva širom svijeta i predstavljala značajan društveno-ekonomski teret (3).</seg>
</tuv>
</tu>
<tu tuid="218">
<prop type="lengthRatio">0.9157894736842105</prop>
<tuv xml:lang="en">
<seg>The World Health Organization (WHO) also recommends vaccination for healthcare workers.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svjetska zdravstvena organizacija (SZO) također preporuča cijepljenje i zdravstvenim radnicima.</seg>
</tuv>
</tu>
<tu tuid="219">
<prop type="lengthRatio">1.1319444444444444</prop>
<tuv xml:lang="en">
<seg>Most EU Member States follow the WHO recommendations to vaccinate pregnant women, and some follow recommendations to vaccinate healthy children aged 6 - 59 months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina država članica EU-a prati preporuke SZO-a o cijepljenju trudnica, a neke i preporuke o cijepljenju zdrave djece u dobi od 6 - 59 mjeseci.</seg>
</tuv>
</tu>
<tu tuid="220">
<prop type="lengthRatio">0.9121621621621622</prop>
<tuv xml:lang="en">
<seg>Even so, about half of the children and working-age adults needing admission to intensive care have no pre-existing medical conditions.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bez obzira na to, gotovo polovica djece i radno sposobnih odraslih osoba čije stanje zahtijeva intenzivnu njegu nemaju drugih zdravstvenih problema.</seg>
</tuv>
</tu>
<tu tuid="221">
<prop type="lengthRatio">1.0307692307692307</prop>
<tuv xml:lang="en">
<seg>Antiviral medicines, taken as rapidly as possible after illness onset, are safe and effective measures for the treatment of influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Protuvirusni lijekovi koji se uzimaju što je prije moguće nakon nastupa bolesti sigurne su i djelotvorne mjere za liječenje gripe.</seg>
</tuv>
</tu>
<tu tuid="222">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>sore throat;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>upaljeno grlo;</seg>
</tuv>
</tu>
<tu tuid="223">
<prop type="lengthRatio">1.316326530612245</prop>
<tuv xml:lang="en">
<seg>Approximately 20% of the population gets infected with influenza each year and one in four infected people will develop symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Gripom se svake godine zarazi otprilike 20 % stanovništva, a svaka četvrta osoba razvije simptome.</seg>
</tuv>
</tu>
<tu tuid="224">
<prop type="lengthRatio">1.164021164021164</prop>
<tuv xml:lang="en">
<seg>The mortality rate due to influenza has been estimated in the EU/EEA countries participating to the EuroMOMO network (1) to be as high as 25 deaths per 100 000 population in the 2016/27 and 2017/18 influenza seasons (2).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stopa smrtnosti zbog gripe procijenjena je u državama EU-a/EGP-a koje sudjeluju u mreži EuroMOMO (1) na 25 smrtnih slučajeva na 100 000 osoba u sezonama gripe 2016./2017. i 2017./2018. (2).</seg>
</tuv>
</tu>
<tu tuid="225">
<prop type="lengthRatio">1.0350877192982457</prop>
<tuv xml:lang="en">
<seg>Vaccination is the most effective way to prevent influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje je najučinkovitiji način za suzbijanje gripe.</seg>
</tuv>
</tu>
<tu tuid="226">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>The EU Member States recommend seasonal influenza vaccination for risk groups, such as the elderly, as well as individuals with chronic medical conditions like heart disease, problems with the lungs and airways, diabetes or immune system problems.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Države članice EU-a preporučuju sezonsko cjepivo protiv gripe za rizične skupine poput starijih osoba i osoba s kroničnim bolestima, kao što su bolesti srca, problemi s plućima i dišnim putevima, dijabetes ili imunosni problemi.</seg>
</tuv>
</tu>
<tu tuid="227">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>In some cases patients develop bacterial complications following influenza infection and need to be treated with antibiotics.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim slučajevima bolesnici razviju bakterijske komplikacije nakon zaraze gripom te im je potrebno liječenje antibioticima.</seg>
</tuv>
</tu>
<tu tuid="228">
<prop type="lengthRatio">0.8714285714285714</prop>
<tuv xml:lang="en">
<seg>Severe illness and complications are more common in very young infants, the frail elderly and certain medical risk groups.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ozbiljan oblik bolesti i komplikacije češći su kod novorođenčadi, krhkih starijih osoba i određenih skupina izloženih zdravstvenim rizicima.</seg>
</tuv>
</tu>
<tu tuid="229">
<prop type="lengthRatio">1.2571428571428571</prop>
<tuv xml:lang="en">
<seg>Animals can also be infected with influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>I životinje mogu oboljeti od gripe.</seg>
</tuv>
</tu>
<tu tuid="230">
<prop type="lengthRatio">1.2372881355932204</prop>
<tuv xml:lang="en">
<seg>A pandemic is the rapid spread of a new human influenza around the world.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pandemija je brzo širenje novog virusa gripe širom svijeta.</seg>
</tuv>
</tu>
<tu tuid="231">
<prop type="lengthRatio">1.0394088669950738</prop>
<tuv xml:lang="en">
<seg>In addition to vaccination, antiviral medicines have been shown to be safe and effective measures to prevent influenza infection or to reduce the severity of infection in certain settings, such as nursing homes.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uz cijepljenje, protuvirusni lijekovi pokazali su se sigurnim i djelotvornim mjerama za suzbijanje infekcije gripom ili u smanjenju težine infekcije na određenim mjestima kao što su domovi umirovljenika.</seg>
</tuv>
</tu>
<tu tuid="232">
<prop type="lengthRatio">0.9457364341085271</prop>
<tuv xml:lang="en">
<seg>People with pre-existing medical conditions are at higher risk of their condition worsening following influenza infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osobe s postojećim zdravstvenim problemima izložene su većem riziku od pogoršanja zdravstvenog stanja nakon što se zaraze gripom.</seg>
</tuv>
</tu>
<tu tuid="233">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>Complications of influenza include pneumonia and encephalitis (inflammation of the brain).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije gripe uključuju upalu pluća i encefalitis (upalu moždanih stanica).</seg>
</tuv>
</tu>
<tu tuid="234">
<prop type="lengthRatio">1.0568181818181819</prop>
<tuv xml:lang="en">
<seg>Influenza pandemics happen when a new strain of a flu virus appears which can infect humans, to which most people have no immunity and which can transmit efficiently from human to human.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Do pandemije gripe dolazi kad se pojavi novi soj virusa gripe koji je zarazan za ljude, protiv kojeg većina ljudi nije razvila imunitet i koji se lako prenosi s osobe na osobu.</seg>
</tuv>
</tu>
<tu tuid="235">
<prop type="lengthRatio">1.1071428571428572</prop>
<tuv xml:lang="en">
<seg>The severity of the disease varies widely, from no symptoms at all through to severe illness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Težina bolesti značajno varira, od izostanka simptoma do vrlo teškog oblika bolesti.</seg>
</tuv>
</tu>
<tu tuid="236">
<prop type="lengthRatio">0.9504950495049505</prop>
<tuv xml:lang="en">
<seg>In some cases, humans can be infected by animals, such as in cases of avian and swine influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se slučajevima ljudi zaraze od životinja, kao što je bio slučaj s ptičjom i svinjskom gripom.</seg>
</tuv>
</tu>
<tu tuid="237">
<prop type="lengthRatio">0.8817204301075269</prop>
<tuv xml:lang="en">
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U slučajevima bez komplikacija simptomi se sami povuku unutar tjedan dana od nastupa bolesti.</seg>
</tuv>
</tu>
<tu tuid="238">
<prop type="lengthRatio">1.0518518518518518</prop>
<tuv xml:lang="en">
<seg>The EU Council Recommendation on seasonal influenza vaccination encourages countries to improve vaccination coverage among healthcare workers.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Preporuka Europskog Vijeća o cijepljenju protiv sezonske gripe potiče zemlje na povećanje procijepljenosti među zdravstvenim radnicima.</seg>
</tuv>
</tu>
<tu tuid="239">
<prop type="lengthRatio">0.7818181818181819</prop>
<tuv xml:lang="en">
<seg>For those that do, common symptoms include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osobe koje se razbole obično razviju sljedeće simptome:</seg>
</tuv>
</tu>
<tu tuid="240">
<prop type="lengthRatio">0.9032258064516129</prop>
<tuv xml:lang="en">
<seg>Who is at risk of influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od gripe?</seg>
</tuv>
</tu>
<tu tuid="241">
<prop type="lengthRatio">1.3877551020408163</prop>
<tuv xml:lang="en">
<seg>Not everyone who is infected with an influenza virus becomes unwell.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ne razboli se svaka osoba zaražena virusom gripe.</seg>
</tuv>
</tu>
<tu tuid="242">
<prop type="lengthRatio">0.9901960784313726</prop>
<tuv xml:lang="en">
<seg>An update of seasonal influenza vaccines is needed yearly, since influenza viruses constantly evolve.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo protiv sezonske gripe svake je godine potrebno izmijeniti jer virus gripe kontinuirano mutira.</seg>
</tuv>
</tu>
<tu tuid="243">
<prop type="lengthRatio">0.7288135593220338</prop>
<tuv xml:lang="en">
<seg>However, antivirals are generally recommended for severe or rapidly progressing cases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, protuvirusni se lijekovi u pravilu preporučuju za teške oblike bolesti i one koji se izuzetno brzo razvijaju.</seg>
</tuv>
</tu>
<tu tuid="244">
<prop type="lengthRatio">1.263157894736842</prop>
<tuv xml:lang="en">
<seg>How is influenza spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se gripa širi?</seg>
</tuv>
</tu>
<tu tuid="245">
<prop type="lengthRatio">1.1195652173913044</prop>
<tuv xml:lang="en">
<seg>In addition to seasonal epidemics, novel influenza viruses may occasionally emerge and cause pandemics.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uz sezonske epidemije gripe, povremeno se razviju novi virusi gripe koji uzrokuju pandemiju.</seg>
</tuv>
</tu>
<tu tuid="246">
<prop type="lengthRatio">1.0333333333333334</prop>
<tuv xml:lang="en">
<seg>How can influenza be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se gripa može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="247">
<prop type="lengthRatio">1.4814814814814814</prop>
<tuv xml:lang="en">
<seg>What are the complications of influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije gripe?</seg>
</tuv>
</tu>
<tu tuid="248">
<prop type="lengthRatio">1.3846153846153846</prop>
<tuv xml:lang="en">
<seg>What is influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je gripa?</seg>
</tuv>
</tu>
<tu tuid="249">
<prop type="lengthRatio">1.6153846153846154</prop>
<tuv xml:lang="en">
<seg>For most cases of influenza, patients are advised to take bed rest and drink plenty of fluids in order to manage their symptoms; staying at home also minimises the risk of infecting others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod većine slučajeva gripe bolesnicima se savjetuje ležanje i uzimanje velike količine tekućine za kontrolu simptoma.</seg>
</tuv>
</tu>
<tu tuid="250">
<prop type="lengthRatio">0.8554216867469879</prop>
<tuv xml:lang="en">
<seg>This is mainly via direct contact with secretions from infectious patients, such as droplets of fluid released when they cough or breathe out.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Gripa se lako širi s osobe na osobu uglavnom putem izravnog kontakta sa sekretom zaraženog bolesnika, kao što su kapljice tekućine koje bolesnik iskašlje ili izdahne.</seg>
</tuv>
</tu>
<tu tuid="251">
<prop type="lengthRatio">1.5217391304347827</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi gripe?</seg>
</tuv>
</tu>
<tu tuid="252">
<prop type="lengthRatio">1.1904761904761905</prop>
<tuv xml:lang="en">
<seg>How is influenza treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se gripa liječi?</seg>
</tuv>
</tu>
<tu tuid="253">
<prop type="lengthRatio">0.6260162601626016</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs in regular annual epidemics in the winter season.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U Europi se gripa javlja kao epidemija tijekom zimskih mjeseci, a epidemiju obilježava visoka stopa hospitalizacije i smrt.</seg>
</tuv>
</tu>
<tu tuid="254">
<prop type="lengthRatio">1.3636363636363635</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="hr">
<seg>glavobolju;</seg>
</tuv>
</tu>
<tu tuid="255">
<prop type="lengthRatio">1.8780487804878048</prop>
<tuv xml:lang="en">
<seg>These epidemics are associated with high hospitalisation rates and mortality.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>vrućicu ili osjećaj povišene temperature;</seg>
</tuv>
</tu>
<tu tuid="256">
<prop type="lengthRatio">1.15</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rubeola (crljenac) je virusna infekcija.</seg>
</tuv>
</tu>
<tu tuid="257">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>In healthy individuals it is usually a mild disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U zdravih pojedinaca rubeola je obično blaga bolest.</seg>
</tuv>
</tu>
<tu tuid="258">
<prop type="lengthRatio">0.8217821782178217</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice su vrlo zarazna virusna bolest od koje se može oboljeti u bilo kojoj dobi i koja se brzo širi.</seg>
</tuv>
</tu>
<tu tuid="259">
<prop type="lengthRatio">0.7352941176470589</prop>
<tuv xml:lang="en">
<seg>When to avoid vaccination</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada treba izbjegavati cijepljenje</seg>
</tuv>
</tu>
<tu tuid="260">
<prop type="lengthRatio">0.8652849740932642</prop>
<tuv xml:lang="en">
<seg>Immunocompromised patients also benefit from those around them being fully vaccinated (such as family members, caregivers), as then they are also indirectly protected.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Imunokompromitirani bolesnici također imaju koristi od toga da su osobe iz njihove okoline cijepljene (poput članova obitelji i pružatelja skrbi) jer su u tom slučaju i oni neizravno zaštićeni.</seg>
</tuv>
</tu>
<tu tuid="261">
<prop type="lengthRatio">0.837037037037037</prop>
<tuv xml:lang="en">
<seg>Anaphylaxis is a rare, rapid, extreme allergic reaction which can cause shock, swelling and difficulty breathing.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Anafilaksija je rijetka, brzo nastupajuća, ekstremno jaka alergijska reakcija koja može uzrokovati šok, oticanje i teškoće pri disanju.</seg>
</tuv>
</tu>
<tu tuid="262">
<prop type="lengthRatio">0.8646153846153846</prop>
<tuv xml:lang="en">
<seg>Certain immune system disorders (e.g. congenital immune deficiencies), or medical treatments (e.g. chemotherapy, a bone marrow or other organ transplant, or high doses of steroids) are contraindications for some vaccines, such as measles, mumps, rubella, varicella or oral typhoid.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Određeni poremećaji imunosnog sustava (poput urođenih imunosnih poremećaja), ili medicinske terapije (poput kemoterapije, presađivanja koštane srži ili organa ili visoke doze steroida) kontraindicirani su za neka cjepiva, kao što je cjepivo protiv ospica, zaušnjaka, rubeole, vodenih kozica i peroralno cjepivo protiv tifusa.</seg>
</tuv>
</tu>
<tu tuid="263">
<prop type="lengthRatio">1.1746031746031746</prop>
<tuv xml:lang="en">
<seg>It usually occurs within minutes of exposure to the source of the allergy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Obično se razvije unutar nekoliko minuta od izlaganja alergenu.</seg>
</tuv>
</tu>
<tu tuid="264">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>In some cases, the completion of the immunisations needed is recommended prior to the start of a treatment, as during the treatment the patient may be at higher risks of infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se slučajevima potrebno cijepljenje preporučuje prije početka terapije jer bolesnik tijekom terapije može biti izložen većem riziku od zaraze.</seg>
</tuv>
</tu>
<tu tuid="265">
<prop type="lengthRatio">1.0072992700729928</prop>
<tuv xml:lang="en">
<seg>Women of childbearing age should discuss with their healthcare provider which vaccines are recommended before, during and after pregnancy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Žene reproduktivne dobi sa svojim se liječnikom trebaju posavjetovati o tome koja su cjepiva preporučena prije, tijekom i nakon trudnoće.</seg>
</tuv>
</tu>
<tu tuid="266">
<prop type="lengthRatio">1.0775193798449612</prop>
<tuv xml:lang="en">
<seg>A vaccine is contraindicated to those allergic to any of the vaccine active substances or ingredients as listed in the product information.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo je kontraindicirano kod osoba koje su alergične na bilo koju aktivnu tvar ili sastojak naveden u informacijama o cjepivu.</seg>
</tuv>
</tu>
<tu tuid="267">
<prop type="lengthRatio">1.018348623853211</prop>
<tuv xml:lang="en">
<seg>There may be other contraindications for specific vaccines, which need discussing with the healthcare provider.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu postojati i druge kontraindikacije za određena cjepiva oko kojih se potrebno posavjetovati s liječnikom.</seg>
</tuv>
</tu>
<tu tuid="268">
<prop type="lengthRatio">1.1261261261261262</prop>
<tuv xml:lang="en">
<seg>Every effort should be made to see that women receive all routinely recommended vaccines before they reach child-bearing age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Potrebno je uložiti maksimalan napor da žene prime sva uobičajeno preporučena cjepiva prije reproduktivne dobi.</seg>
</tuv>
</tu>
<tu tuid="269">
<prop type="lengthRatio">1.0203045685279188</prop>
<tuv xml:lang="en">
<seg>Someone who experiences an anaphylactic or other serious allergic reaction following a certain vaccine should not be given that vaccine again, unless the vaccine is definitively ruled out as the cause.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osoba koja doživi anafilaktičku reakciju ili drugu ozbiljnu alergijsku reakciju nakon određenog cjepiva ne smije više primiti to cjepivo, osim ako je ono u potpunosti isključeno kao uzrok alergije.</seg>
</tuv>
</tu>
<tu tuid="270">
<prop type="lengthRatio">0.8969072164948454</prop>
<tuv xml:lang="en">
<seg>Some vaccines are contraindicated during pregnancy, such as measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neka su cjepiva kontraindicirana tijekom trudnoće, poput onih protiv ospica, zaušnjaka i rubeole.</seg>
</tuv>
</tu>
<tu tuid="271">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>A history of 'anaphylactic' or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Anafilaksija ili druge ozbiljne alergijske reakcije nakon cijepljenja kontraindikacija su za dodatne doze istog cjepiva.</seg>
</tuv>
</tu>
<tu tuid="272">
<prop type="lengthRatio">2.3411764705882354</prop>
<tuv xml:lang="en">
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it. Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih osoba cjepivo može biti kontraindicirano, što znači da ga ne smiju primiti.</seg>
</tuv>
</tu>
<tu tuid="273">
<prop type="lengthRatio">2.3333333333333335</prop>
<tuv xml:lang="en">
<seg>These include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To su:</seg>
</tuv>
</tu>
<tu tuid="274">
<prop type="lengthRatio">0.8</prop>
<tuv xml:lang="en">
<seg>An example is aluminium;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedan od primjera je aluminij;</seg>
</tuv>
</tu>
<tu tuid="275">
<prop type="lengthRatio">1.1846153846153846</prop>
<tuv xml:lang="en">
<seg>In addition to one or more antigens, there are other components in a vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osim jednog ili više antigena, cjepivo sadržava i druge sastojke.</seg>
</tuv>
</tu>
<tu tuid="276">
<prop type="lengthRatio">1.1238938053097345</prop>
<tuv xml:lang="en">
<seg>adjuvants: these improve the immune response to the vaccine by making the response stronger, faster and more sustained in time.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>adjuvansi: koji poboljšavaju imunosni odgovor na cjepivo i čine ga snažnijim, bržim i održivijim tijekom vremena.</seg>
</tuv>
</tu>
<tu tuid="277">
<prop type="lengthRatio">0.9661016949152542</prop>
<tuv xml:lang="en">
<seg>These substances are consistently controlled to ensure they are present at levels that have been shown to be safe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Te su tvari pod konstantnim nadzorom kako bi se osiguralo da su prisutne u razinama za koje se pokazalo da su sigurne.</seg>
</tuv>
</tu>
<tu tuid="278">
<prop type="lengthRatio">0.9950248756218906</prop>
<tuv xml:lang="en">
<seg>excipients: these are inactive ingredients, like water, or sodium chloride (salt), as well as the preservatives or stabilisers that help the vaccine remain unchanged during storage, keeping it active.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>pomoćne tvari: to su neaktivni sastojci, poput vode ili natrijevog klorida (soli), kao i konzervansa ili stabilizatora kojima se postiže da cjepivo tijekom skladištenja ostane nepromijenjeno i aktivno.</seg>
</tuv>
</tu>
<tu tuid="279">
<prop type="lengthRatio">0.8348623853211009</prop>
<tuv xml:lang="en">
<seg>Regulators check that their benefits are weighed against the risk of any reactions to them.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Regulatorna tijela provjeravaju omjer njihove koristi u odnosu na rizike koje reakcije na njih mogu izazvati.</seg>
</tuv>
</tu>
<tu tuid="280">
<prop type="lengthRatio">1.0136363636363637</prop>
<tuv xml:lang="en">
<seg>Whenever these substances are present at a level that might trigger a reaction in a sensitive or allergic individual, their presence is declared in the information provided to healthcare workers and patients on the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uvijek kada se te tvari nalaze u razinama koje mogu izazvati reakciju u osjetljivih ili alergičnih osoba njihova se prisutnost prijavi putem informacija o cjepivu koje se dostavljaju zdravstvenim radnicima i bolesnicima.</seg>
</tuv>
</tu>
<tu tuid="281">
<prop type="lengthRatio">0.9408284023668639</prop>
<tuv xml:lang="en">
<seg>There may also be trace amounts of other substances used in the manufacturing process, such as ovalbumin (a protein found in eggs) or neomycin (an antibiotic).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tragovima mogu biti prisutne i druge tvari koje se koriste u proizvodnom postupku, poput ovalbumina (bjelančevine koja se nalazi u jajima) ili neomicina (antibiotika).</seg>
</tuv>
</tu>
<tu tuid="282">
<prop type="lengthRatio">1.0194174757281553</prop>
<tuv xml:lang="en">
<seg>For example, the package leaflet will state if there are special precautions for use of a vaccine in people with certain allergies, such as vaccines including trace amounts of egg in people with an egg allergy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, upute o cjepivu sadržavat će informacije o posebnim mjerama opreza pri uporabi za osobe s određenim alergijama, poput onih za cjepiva koja sadržavaju jaje u tragovima za osobe alergične na jaja.</seg>
</tuv>
</tu>
<tu tuid="283">
<prop type="lengthRatio">0.88</prop>
<tuv xml:lang="en">
<seg>Thanks to vaccination:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju:</seg>
</tuv>
</tu>
<tu tuid="284">
<prop type="lengthRatio">1.04</prop>
<tuv xml:lang="en">
<seg>Vaccination programmes have wider societal benefits.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Programi cijepljenja imaju šire društvene koristi.</seg>
</tuv>
</tu>
<tu tuid="285">
<prop type="lengthRatio">0.8517241379310345</prop>
<tuv xml:lang="en">
<seg>They help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Oni doprinose smanjenju društvenog, psihološkog i financijskog tereta koji bolesti nameću stanovništvu i državnim institucijama, smanjuje se opterećenje sustava zdravstvene i socijalne skrbi te omogućuje ljudima da se slobodno bave produktivnim aktivnostima, kao što su obrazovanje i posao.</seg>
</tuv>
</tu>
<tu tuid="286">
<prop type="lengthRatio">1.1237113402061856</prop>
<tuv xml:lang="en">
<seg>Vaccination also prevents the development of certain types of pre-cancerous growths and cancers, for example:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se sprječava i razvoj određenih vrsta pretkancerogenih izraslina i raka, primjerice:</seg>
</tuv>
</tu>
<tu tuid="287">
<prop type="lengthRatio">1.167883211678832</prop>
<tuv xml:lang="en">
<seg>The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Spojene točke označavaju najveći i najmanji broj prethodno nezaraženih i necijepljenih osoba koje bi se mogle zaraziti od oboljele osobe.</seg>
</tuv>
</tu>
<tu tuid="288">
<prop type="lengthRatio">0.9389312977099237</prop>
<tuv xml:lang="en">
<seg>This shows both the most conservative estimate (inner ring, darker dots) and the maximum estimate (outer ring, paler dots).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prikazana je i procjena najmanjeg broja (unutarnji krug, tamnije točke) i procjena najvećeg broja (vanjski krug, svijetlije točke).</seg>
</tuv>
</tu>
<tu tuid="289">
<prop type="lengthRatio">0.984375</prop>
<tuv xml:lang="en">
<seg>Vaccination helps prevent the spread of disease in communities.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje pomaže u sprječavanju širenja bolesti u zajednicama.</seg>
</tuv>
</tu>
<tu tuid="290">
<prop type="lengthRatio">0.927710843373494</prop>
<tuv xml:lang="en">
<seg>transmission of polio has ended in most parts of the world, including Europe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>zaraza dječjom paralizom suzbijena je u većem dijelu svijeta, uključujući u Europi.</seg>
</tuv>
</tu>
<tu tuid="291">
<prop type="lengthRatio">1.2608695652173914</prop>
<tuv xml:lang="en">
<seg>The centre dot represent one person affected by a disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Središnja točka označava jednu oboljelu osobu.</seg>
</tuv>
</tu>
<tu tuid="292">
<prop type="lengthRatio">0.8041958041958042</prop>
<tuv xml:lang="en">
<seg>vaccinating against humanpapilloma virus (HPV) can help prevent cervical and other cancers caused by HPV infection;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>cijepljenjem protiv humanog papilomavirusa (HPV) moguće je spriječiti rak grlića maternice i druge vrste raka koje su posljedica zaraze HPV-om;</seg>
</tuv>
</tu>
<tu tuid="293">
<prop type="lengthRatio">1.1566265060240963</prop>
<tuv xml:lang="en">
<seg>When a large percentage of a population is vaccinated, infectious diseases cannot easily spread.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako je procijepljen visok postotak populacije, otežano je širenje zaraznih bolesti.</seg>
</tuv>
</tu>
<tu tuid="294">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>Vaccination prevents people from getting the symptoms of the disease, which can be severe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se sprječava izbijanje simptoma bolesti, koji mogu biti teški.</seg>
</tuv>
</tu>
<tu tuid="295">
<prop type="lengthRatio">0.9724137931034482</prop>
<tuv xml:lang="en">
<seg>Vaccination is the best way to acquire immunity against vaccine-preventable diseases, as opposed to immunity attained by getting the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje je najbolji način stjecanja imunosti na bolesti koje se mogu spriječiti cijepljenjem, za razliku od imunosti stečene tijekom bolesti.</seg>
</tuv>
</tu>
<tu tuid="296">
<prop type="lengthRatio">1.0612244897959184</prop>
<tuv xml:lang="en">
<seg>vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>cijepljenjem protiv hepatitisa B moguće je spriječiti rak jetre uzrokovan kroničnim hepatitisom B.</seg>
</tuv>
</tu>
<tu tuid="297">
<prop type="lengthRatio">0.8043478260869565</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>velike boginje iskorijenjene su širom svijeta;</seg>
</tuv>
</tu>
<tu tuid="298">
<prop type="lengthRatio">0.42696629213483145</prop>
<tuv xml:lang="en">
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To je poznato pod nazivom „kolektivna imunost" (koja se ponekad još naziva i „imunost krda") Cijepljenjem je moguće iskorijeniti bolesti ili znatno smanjiti broj novih slučajeva.</seg>
</tuv>
</tu>
<tu tuid="299">
<prop type="lengthRatio">1.121212121212121</prop>
<tuv xml:lang="en">
<seg>When symptoms do occur, they include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako nastupe simptomi, onda su to:</seg>
</tuv>
</tu>
<tu tuid="300">
<prop type="lengthRatio">0.75</prop>
<tuv xml:lang="en">
<seg>red rash;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>crveni osip;</seg>
</tuv>
</tu>
<tu tuid="301">
<prop type="lengthRatio">1.0990990990990992</prop>
<tuv xml:lang="en">
<seg>The second dose can be given one month or more after the first dose, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Druga doza može se dati mjesec dana nakon prve doze ili kasnije, u skladu s nacionalnim rasporedom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="302">
<prop type="lengthRatio">1.077922077922078</prop>
<tuv xml:lang="en">
<seg>The first dose is given between 10 and 18 months of age in most European countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prva se doza u većini europskih zemalja daje između 10. i 18. mjeseca života.</seg>
</tuv>
</tu>
<tu tuid="303">
<prop type="lengthRatio">1.3191489361702127</prop>
<tuv xml:lang="en">
<seg>swollen lymph glands around the ears and the back of the head;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>otečeni limfni čvorovi oko ušiju i na potiljku;</seg>
</tuv>
</tu>
<tu tuid="304">
<prop type="lengthRatio">1.18</prop>
<tuv xml:lang="en">
<seg>Two doses of the vaccine are needed for maximum protection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za potpunu zaštitu potrebne su dvije doze cjepiva.</seg>
</tuv>
</tu>
<tu tuid="305">
<prop type="lengthRatio">1.1129032258064515</prop>
<tuv xml:lang="en">
<seg>Up to 50% of people infected with rubella do not experience symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Do 50 % osoba zaraženih virusom rubeole nema nikakve simptome.</seg>
</tuv>
</tu>
<tu tuid="306">
<prop type="lengthRatio">1.0793650793650793</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective and has very few side effects.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR sigurno je i učinkovito te ima vrlo malo nuspojava.</seg>
</tuv>
</tu>
<tu tuid="307">
<prop type="lengthRatio">0.8947368421052632</prop>
<tuv xml:lang="en">
<seg>However, if a woman gets rubella during the first three months of pregnancy, it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome (CRS).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, ako žena tijekom prva tri mjeseca trudnoće oboli od rubeole, vrlo je vjerojatno da će doći do spontanog pobačaja ili da će novorođenče imati kongenitalnu anomaliju poznatu pod nazivom kongenitalni sindrom rubeole (CRS).</seg>
</tuv>
</tu>
<tu tuid="308">
<prop type="lengthRatio">0.9539473684210527</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih primatelja cjepiva razvije se neinfektivni blagi osip nalik ospicama, u pravilu 7 do14 dana nakon cijepljenja i nestaje u roku od 1 do 3 dana.</seg>
</tuv>
</tu>
<tu tuid="309">
<prop type="lengthRatio">1.0227272727272727</prop>
<tuv xml:lang="en">
<seg>Women who plan to become pregnant should check their vaccination status, as they cannot be vaccinated against rubella during pregnancy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Žene koje planiraju trudnoću trebale bi provjeriti svoj status cijepljenja jer se tijekom trudnoće ne smiju cijepiti protiv rubeole.</seg>
</tuv>
</tu>
<tu tuid="310">
<prop type="lengthRatio">1.4375</prop>
<tuv xml:lang="en">
<seg>pain and inflammation of the joints in adults.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>bol i upala zglobova u odraslih.</seg>
</tuv>
</tu>
<tu tuid="311">
<prop type="lengthRatio">1.2474226804123711</prop>
<tuv xml:lang="en">
<seg>Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko tko nije prebolio tu bolest ili nije primio cjepivo MMR u opasnosti je od zaraze rubeolom.</seg>
</tuv>
</tu>
<tu tuid="312">
<prop type="lengthRatio">0.9381443298969072</prop>
<tuv xml:lang="en">
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prijavljene su blage nuspojave poput vrućice, crvenila ili oticanja na mjestu primjene injekcije.</seg>
</tuv>
</tu>
<tu tuid="313">
<prop type="lengthRatio">0.952</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR (protiv ospica, zaušnjaka i rubeole) kombinirano je cjepivo koje nas je nas štiti od ospica, zaušnjaka i rubeole.</seg>
</tuv>
</tu>
<tu tuid="314">
<prop type="lengthRatio">0.7878787878787878</prop>
<tuv xml:lang="en">
<seg>Who is at risk of rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od rubeole?</seg>
</tuv>
</tu>
<tu tuid="315">
<prop type="lengthRatio">0.90625</prop>
<tuv xml:lang="en">
<seg>How can rubella be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se rubeola može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="316">
<prop type="lengthRatio">1.32</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi rubeole?</seg>
</tuv>
</tu>
<tu tuid="317">
<prop type="lengthRatio">1.1195652173913044</prop>
<tuv xml:lang="en">
<seg>The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Virus rubeole širi se zrakom u kapljicama koje nastaju kašljanjem i kihanjem zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="318">
<prop type="lengthRatio">1.0476190476190477</prop>
<tuv xml:lang="en">
<seg>How is rubella spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se rubeola širi?</seg>
</tuv>
</tu>
<tu tuid="319">
<prop type="lengthRatio">0.9279279279279279</prop>
<tuv xml:lang="en">
<seg>The consequences for unvaccinated pregnant women that get rubella are particularly severe, due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Posljedice za necijepljene trudnice koje obole od rubeole posebno su ozbiljne zbog vjerojatnosti da obolijevanje tijekom trudnoće može uzrokovati spontani pobačaj ili kongenitalni sindrom rubeole kod njihove novorođenčadi.</seg>
</tuv>
</tu>
<tu tuid="320">
<prop type="lengthRatio">1.2439024390243902</prop>
<tuv xml:lang="en">
<seg>The only protection against rubella is vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina zaštita od bolesti je cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="321">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>How is rubella treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se rubeola liječi?</seg>
</tuv>
</tu>
<tu tuid="322">
<prop type="lengthRatio">0.8604651162790697</prop>
<tuv xml:lang="en">
<seg>CRS can lead to deafness, cataracts and learning disabilities in the baby.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kongenitalni sindrom rubeole može uzrokovati gluhoću, katarktu i poteškoće pri učenju.</seg>
</tuv>
</tu>
<tu tuid="323">
<prop type="lengthRatio">0.8260869565217391</prop>
<tuv xml:lang="en">
<seg>What are the complications of rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su moguće komplikacije izazvane rubeolom?</seg>
</tuv>
</tu>
<tu tuid="324">
<prop type="lengthRatio">0.9183673469387755</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija potražite na mrežnom mjestu ECDC-a: https://www.ecdc.europa.eu/hr/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="325">
<prop type="lengthRatio">1.0761421319796953</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Napomena: Informacije iznesene u ovom članku namijenjene su potrebama općeg informiranja i ne bi se smjele upotrebljavati kao zamjena za pojedinačne stručne savjete i prosudbe zdravstvenih radnika.</seg>
</tuv>
</tu>
<tu tuid="326">
<prop type="lengthRatio">0.9494949494949495</prop>
<tuv xml:lang="en">
<seg>Symptoms usually appear 7 to 10 days after infection, but may also appear up to 21 days later:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Simptomi se obično javljaju 7 do 10 dana nakon infekcije, ali mogu se pojaviti i do 21 dan kasnije.</seg>
</tuv>
</tu>
<tu tuid="327">
<prop type="lengthRatio">1.305084745762712</prop>
<tuv xml:lang="en">
<seg>It is caused by bacteria in the mouth, nose and throat of an infected person.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uzrokuju ga bakterije u ustima, nosu i grlu zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="328">
<prop type="lengthRatio">1.875</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac</seg>
</tuv>
</tu>
<tu tuid="329">
<prop type="lengthRatio">0.9814814814814815</prop>
<tuv xml:lang="en">
<seg>Adolescents, adults, or children partially immunised generally have milder or somewhat different symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Adolescenti, odrasli i djeca koja su djelomično procijepljena obično imaju blaže ili malo drukčije simptome.</seg>
</tuv>
</tu>
<tu tuid="330">
<prop type="lengthRatio">1.1808510638297873</prop>
<tuv xml:lang="en">
<seg>They initially occur at night and then become more frequent during the day and may recur for one to two months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na početku se javljaju noću, a kasnije postaju sve češći danju i mogu potrajati mjesec do dva.</seg>
</tuv>
</tu>
<tu tuid="331">
<prop type="lengthRatio">0.8405797101449275</prop>
<tuv xml:lang="en">
<seg>A third or fourth dose is recommended at 11-24 months of age, and another dose between three and seven years of age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Treću ili četvrtu dozu preporučuje se dati u dobi od 11 do 24 mjeseca, nakon čega slijedi još jedna doza u dobi između tri i sedam godina.</seg>
</tuv>
</tu>
<tu tuid="332">
<prop type="lengthRatio">0.8235294117647058</prop>
<tuv xml:lang="en">
<seg>Who is at risk of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od hripavca?</seg>
</tuv>
</tu>
<tu tuid="333">
<prop type="lengthRatio">0.994413407821229</prop>
<tuv xml:lang="en">
<seg>However, in order to be most effective, treatment must begin early in the course of disease, during the first one to two weeks before the episodes of numerous rapid coughs occur.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, kako bi bilo što učinkovitije, liječenje mora započeti u ranoj fazi bolesti, odnosno tijekom prvih tjedan do dva prije nego se jave napadi s brojnim brzim udarima kašlja.</seg>
</tuv>
</tu>
<tu tuid="334">
<prop type="lengthRatio">1.064</prop>
<tuv xml:lang="en">
<seg>Frequently, older siblings and parents who may be carrying the bacteria bring the disease home and infect an infant in the household.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Često se događa da starija braća ili roditelji koji mogu biti nositelji bakterija donesu bolest u kuću i tako zaraze dojenče.</seg>
</tuv>
</tu>
<tu tuid="335">
<prop type="lengthRatio">1.311926605504587</prop>
<tuv xml:lang="en">
<seg>Pertussis can also be spread by an individual who has only a mild form of the disease, or by an infected individual who has no symptoms at all.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac može širiti i osoba koja ima samo blag oblik bolesti ili zaražena osoba koja nema nikakvih simptoma.</seg>
</tuv>
</tu>
<tu tuid="336">
<prop type="lengthRatio">1.042857142857143</prop>
<tuv xml:lang="en">
<seg>After this phase, the coughing fits become less frequent and less severe, and the infant gradually gets better (this can take up to three months).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon te faze napadi kašlja postaju rjeđi i slabiji, a stanje dojenčeta postupno se poboljšava (za što može biti potrebno i do tri mjeseca).</seg>
</tuv>
</tu>
<tu tuid="337">
<prop type="lengthRatio">1.054421768707483</prop>
<tuv xml:lang="en">
<seg>Some countries also recommend a booster to unprotected women soon after they have delivered, to reduce the risk of transmission of the disease to the baby.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se zemljama preporučuje i docjepljivanje nezaštićenih žena ubrzo nakon poroda kako bi se smanjio rizik od prijenosa bolesti na novorođenče.</seg>
</tuv>
</tu>
<tu tuid="338">
<prop type="lengthRatio">1.0534351145038168</prop>
<tuv xml:lang="en">
<seg>A primary course of 2-3 doses is usually given between two and twelve months of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prva terapija od dvije do tri doze obično se daje u dobi od dva do dvanaest mjeseci, u skladu s nacionalnim rasporedom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="339">
<prop type="lengthRatio">1.2419354838709677</prop>
<tuv xml:lang="en">
<seg>The most important way to prevent pertussis is through complete immunisation.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Najvažniji način sprječavanja hripavca je potpuno cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="340">
<prop type="lengthRatio">1.065217391304348</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije uključuju upalu pluća, encefalopatiju (bolest mozga), konvulzije pa čak i smrt.</seg>
</tuv>
</tu>
<tu tuid="341">
<prop type="lengthRatio">1.0416666666666667</prop>
<tuv xml:lang="en">
<seg>The most severe forms of pertussis are in infants.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Najteži oblici hripavca javljaju se u dojenčadi.</seg>
</tuv>
</tu>
<tu tuid="342">
<prop type="lengthRatio">1.0423280423280423</prop>
<tuv xml:lang="en">
<seg>The vaccine for pertussis is usually given in combination with diphtheria and tetanus vaccination (often in combination also with poliomyelitis, Haemophilus influenzae and hepatitis B vaccination).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo protiv hripavca obično se daje u kombinaciji s cjepivima protiv difterije i tetanusa (često u kombinaciji i s cjepivima protiv dječje paralize, hemofilusa influence i hepatitisa B).</seg>
</tuv>
</tu>
<tu tuid="343">
<prop type="lengthRatio">0.8837209302325582</prop>
<tuv xml:lang="en">
<seg>In these groups, and in very young infants, pertussis is harder to diagnose.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tim skupinama, kao i u djece rane dojenačke dobi, hripavac je teže dijagnosticirati.</seg>
</tuv>
</tu>
<tu tuid="344">
<prop type="lengthRatio">1.03125</prop>
<tuv xml:lang="en">
<seg>In young infants the typical 'whoop' may never develop, and the coughing fits may be followed by brief periods when breathing stops.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U dojenčadi se možda nikad neće razviti tipični „hrip", a nakon napada kašlja mogu slijediti kratka razdoblja prestanka disanja.</seg>
</tuv>
</tu>
<tu tuid="345">
<prop type="lengthRatio">0.9393939393939394</prop>
<tuv xml:lang="en">
<seg>How can pertussis be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="346">
<prop type="lengthRatio">0.9568345323741008</prop>
<tuv xml:lang="en">
<seg>In adults and older children, complications include inability to breathe for short periods, broken ribs, rectal prolapse and hernias.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U odraslih osoba i veće djece komplikacije obuhvaćaju kratkotrajnu nemogućnost disanja, slomljena rebra, rektalni prolaps i herniju (kilu).</seg>
</tuv>
</tu>
<tu tuid="347">
<prop type="lengthRatio">0.872</prop>
<tuv xml:lang="en">
<seg>Initially, symptoms resemble those of a common cold (sneezing, runny nose, low-grade fever and a mild cough).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na početku simptomi nalikuju simptomima obične prehlade (kihanje, curenje iz nosa, malo povišena temperatura i blagi kašalj).</seg>
</tuv>
</tu>
<tu tuid="348">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>What is pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je hripavac?</seg>
</tuv>
</tu>
<tu tuid="349">
<prop type="lengthRatio">1.064102564102564</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac je vrlo zarazna bakterijska bolest koja zahvaća pluća i dišne putove.</seg>
</tuv>
</tu>
<tu tuid="350">
<prop type="lengthRatio">1.3461538461538463</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi hripavca?</seg>
</tuv>
</tu>
<tu tuid="351">
<prop type="lengthRatio">1.06993006993007</prop>
<tuv xml:lang="en">
<seg>Within two weeks, the cough becomes more severe and is characterized by episodes of numerous rapid coughs, followed by a crowing or high-pitched ‘whoop'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U sljedeća dva tjedna kašalj se pojačava, a za tu fazu tipični su brojni brzi udari kašlja nakon kojih slijedi glasan piskav udisaj ili „hrip".</seg>
</tuv>
</tu>
<tu tuid="352">
<prop type="lengthRatio">1.2033898305084745</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated with the pertussis vaccine, or whose vaccination status is not up-to-date, is at risk of contracting the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko tko nije cijepljen protiv hripavca ili tko nije primio sve potrebne doze cjepiva može se zaraziti ovom bolešću.</seg>
</tuv>
</tu>
<tu tuid="353">
<prop type="lengthRatio">0.9659090909090909</prop>
<tuv xml:lang="en">
<seg>Antibiotics can be used to treat pertussis and prevent further spread of the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za liječenje hripavca i sprječavanje širenja bolesti mogu se upotrebljavati antibiotici.</seg>
</tuv>
</tu>
<tu tuid="354">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije izazvane hripavcem?</seg>
</tuv>
</tu>
<tu tuid="355">
<prop type="lengthRatio">1.375</prop>
<tuv xml:lang="en">
<seg>Some EU/EEA countries recommend boosters for adolescents, adults, and/or women during pregnancy, which also temporarily protects the baby once it is born.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim državama članicama EU-a/EGP-a preporučuje se docjepljivanje adolescenata, odraslih osoba i/ili trudnica.</seg>
</tuv>
</tu>
<tu tuid="356">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>How is pertussis spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac širi?</seg>
</tuv>
</tu>
<tu tuid="357">
<prop type="lengthRatio">1.0416666666666667</prop>
<tuv xml:lang="en">
<seg>How is pertussis treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac liječi?</seg>
</tuv>
</tu>
<tu tuid="358">
<prop type="lengthRatio">1.09375</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Poznat je i pod imenom pertusis.</seg>
</tuv>
</tu>
<tu tuid="359">
<prop type="lengthRatio">0.8292682926829268</prop>
<tuv xml:lang="en">
<seg>Pertussis in unvaccinated infants or infants whose mother was unvaccinated can be particularly severe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac može poprimiti posebno teške oblike u dojenčadi koja nije cijepljenja ili u dojenčadi čije majke nisu cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="360">
<prop type="lengthRatio">1.275</prop>
<tuv xml:lang="en">
<seg>These episodes frequently end with the expulsion of a thick, clear mucous, often followed by vomiting.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Napadi kašlja često završavaju izbacivanjem guste, prozirne sluzi i povraćanjem.</seg>
</tuv>
</tu>
<tu tuid="361">
<prop type="lengthRatio">0.9540229885057471</prop>
<tuv xml:lang="en">
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac se širi zrakom u kapljicama koje nastaju kašljanjem i kihanjem zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="362">
<prop type="lengthRatio">1.1818181818181819</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for their health, for example:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se osobe štiti od bolesti koje mogu imati ozbiljne posljedice za zdravlje, kao što su:</seg>
</tuv>
</tu>
<tu tuid="363">
<prop type="lengthRatio">0.9769230769230769</prop>
<tuv xml:lang="en">
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>hripavac (pertussis), koji može biti posebno opasan za novorođenčad jer uzrokuje napade kašlja koji mogu trajati i do dva mjeseca.</seg>
</tuv>
</tu>
<tu tuid="364">
<prop type="lengthRatio">0.9900990099009901</prop>
<tuv xml:lang="en">
<seg>This list with examples includes diseases for which vaccines are included in the national immunisation programmes, and/or are given to persons considered to be at a higher risk of getting the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ovaj popis primjera obuhvaća bolesti protiv kojih je cjepivo uključeno u nacionalne programe cijepljenja, a također ga se može davati osobama za koje se smatra da su sklonije zarazi od određene bolesti.</seg>
</tuv>
</tu>
<tu tuid="365">
<prop type="lengthRatio">1.0851063829787233</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death (5).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije uključuju upalu pluća, encefalopatiju (bolest mozga), napadaje pa čak i smrt (5).</seg>
</tuv>
</tu>
<tu tuid="366">
<prop type="lengthRatio">1.0641711229946524</prop>
<tuv xml:lang="en">
<seg>almost 9 out of 10 babies born to mothers who had rubella in early pregnancy, will suffer from congenital rubella syndrome (with conditions such as deafness, cataracts and learning disabilities) (2);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>gotovo 9 od 10 beba čije su majke preboljele rubeolu u ranoj trudnoći razvija sindrom kongenitalne rubeole (koji uključuje poremećaje poput gluhoće, katarakte i poteškoća pri učenju) (2);</seg>
</tuv>
</tu>
<tu tuid="367">
<prop type="lengthRatio">0.9903846153846154</prop>
<tuv xml:lang="en">
<seg>meningococcal disease kills 1 in 10 people affected, even with prompt diagnosis and treatment, while problems including neurological or hearing impairment and amputation occur in up to 20% of survivors (3);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>meningokokna bolest, koja ubija svaku desetu oboljelu osobu, čak i uz brzo dijagnosticiranje i liječenje, dok su neurološki poremećaji, oštećenje sluha i amputacije zabilježeni kod 20 % preživjelih osoba (3);</seg>
</tuv>
</tu>
<tu tuid="368">
<prop type="lengthRatio">0.961038961038961</prop>
<tuv xml:lang="en">
<seg>diphtheria kills 1 in every 10 people who get it, even with treatment (1);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>difterija, koja ubija svaku desetu oboljelu osobu, čak i nakon liječenja (1);</seg>
</tuv>
</tu>
<tu tuid="369">
<prop type="lengthRatio">0.97</prop>
<tuv xml:lang="en">
<seg>measles is highly contagious and 3 out of 10 people affected develop complications (4), which can include ear infection, diarrhoea, pneumonia and encephalitis (inflammation of the brain tissue);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ospice, koje su izuzetno zarazna bolest pri kojoj svaka treća oboljela osoba razvija komplikacije (4), koje mogu uključivati infekciju uha, proljev, upalu pluća i encefalitis (upalu moždanih stanica);</seg>
</tuv>
</tu>
<tu tuid="370">
<prop type="lengthRatio">0.8681318681318682</prop>
<tuv xml:lang="en">
<seg>(1) ECDC factsheet - Diphtheria: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(1) Informativni sažetak ECDC-a - Difterija: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
</tu>
<tu tuid="371">
<prop type="lengthRatio">0.8651685393258427</prop>
<tuv xml:lang="en">
<seg>(5) ECDC factsheet - Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(5) Informativni sažetak ECDC-a - Hripavac: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="372">
<prop type="lengthRatio">0.889763779527559</prop>
<tuv xml:lang="en">
<seg>(2) ECDC factsheet - Congenital Rubella Syndrome: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(2) Informativni sažetak ECDC-a - Sindrom kongenitalne rubeole: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
</tu>
<tu tuid="373">
<prop type="lengthRatio">0.9565217391304348</prop>
<tuv xml:lang="en">
<seg>It analyses many sources of data, including:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Analizira brojne izvore podataka, uključujući:</seg>
</tuv>
</tu>
<tu tuid="374">
<prop type="lengthRatio">1.1549295774647887</prop>
<tuv xml:lang="en">
<seg>This ensures that any possible risks are detected and managed as soon as possible.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Time se osigurava što ranije otkrivanje i kontrola svih mogućih rizika.</seg>
</tuv>
</tu>
<tu tuid="375">
<prop type="lengthRatio">1.1318681318681318</prop>
<tuv xml:lang="en">
<seg>The process of monitoring the safety and managing the risks of medicines is called ‘pharmacovigilance'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postupak praćenja sigurnosti i upravljanja rizicima od lijekova zove se farmakovigilancija.</seg>
</tuv>
</tu>
<tu tuid="376">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>EMA checks new information on the safety of all vaccines available in Europe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA provjerava nove informacije o sigurnosti svih cjepiva dostupnih u Europi.</seg>
</tuv>
</tu>
<tu tuid="377">
<prop type="lengthRatio">1.4285714285714286</prop>
<tuv xml:lang="en">
<seg>reports from patients, parents and healthcare professionals;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>izvješća bolesnika, roditelja i liječnika;</seg>
</tuv>
</tu>
<tu tuid="378">
<prop type="lengthRatio">0.7878787878787878</prop>
<tuv xml:lang="en">
<seg>For more information, see:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija potražite ovdje:</seg>
</tuv>
</tu>
<tu tuid="379">
<prop type="lengthRatio">1.008</prop>
<tuv xml:lang="en">
<seg>For example, they can provide updated guidance to healthcare workers, or even restrict the use of a vaccine in certain groups.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, izdaju ažurirane smjernice zdravstvenim radnicima, a ponekad ograničavaju primjenu cjepiva u određenim skupinama.</seg>
</tuv>
</tu>
<tu tuid="380">
<prop type="lengthRatio">0.9081632653061225</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon što je cjepivo odobreno za primjenu, nacionalna nadležna tijela u državama EU-a / EGP-a i Europska agencija za lijekove (EMA), kontinuirano prate nuspojave kod osoba koje su primile cjepivo.</seg>
</tuv>
</tu>
<tu tuid="381">
<prop type="lengthRatio">0.7222222222222222</prop>
<tuv xml:lang="en">
<seg>information shared by other regulators.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>informacije koje razmjenjuju druga regulatorna tijela.</seg>
</tuv>
</tu>
<tu tuid="382">
<prop type="lengthRatio">1.0380952380952382</prop>
<tuv xml:lang="en">
<seg>EMA carefully assesses suspected side effects to determine if there is a causal link with the vaccine or not.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA detaljno procjenjuje sumnje na nuspojave kako bi utvrdila postoji li uzročna veza sa cjepivom ili ne.</seg>
</tuv>
</tu>
<tu tuid="383">
<prop type="lengthRatio">1.1755725190839694</prop>
<tuv xml:lang="en">
<seg>Patients, healthcare professionals and pharmaceutical companies should report all suspected side effects to their national medicines regulatory authority.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bolesnici, liječnici i farmaceutske tvrtke trebaju prijaviti sve sumnje na nuspojave nacionalnim regulatornim tijelima za lijekove.</seg>
</tuv>
</tu>
<tu tuid="384">
<prop type="lengthRatio">0.8176100628930818</prop>
<tuv xml:lang="en">
<seg>This helps to rule out the possibility that it was a coincidence or that it was caused by factors unrelated to the vaccine itself.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tim se pristupom doprinosi isključivanju mogućnosti da se radilo o slučajnosti ili da su nuspojave uzrokovane čimbenicima koji nisu povezani sa samim cjepivom.</seg>
</tuv>
</tu>
<tu tuid="385">
<prop type="lengthRatio">1.1967213114754098</prop>
<tuv xml:lang="en">
<seg>These could be due to an illness or anxiety over being given the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>One mogu biti posljedica bolesti ili stresa zbog cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="386">
<prop type="lengthRatio">0.8873239436619719</prop>
<tuv xml:lang="en">
<seg>When needed, EMA and the other European regulators take action.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA i druga europska regulatorna tijela poduzimaju mjere prema potrebi.</seg>
</tuv>
</tu>
<tu tuid="387">
<prop type="lengthRatio">1.0746268656716418</prop>
<tuv xml:lang="en">
<seg>Information on these reported suspected side effects is publicly available on the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Informacije o prijavljenim sumnjama na nuspojave javno su dostupne u europskoj bazi podataka za prijavu sumnji na nuspojave lijekova .</seg>
</tuv>
</tu>
<tu tuid="388">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>More information on how to report suspected side effects can be found in the prescribing information or package leaflet or the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija o izvješćivanju o sumnjama na nuspojave nalazi se u informacijama za propisivanje, u uputi o cjepivu ili u europskoj bazi podataka za prijavu sumnji na nuspojave lijekova .</seg>
</tuv>
</tu>
<tu tuid="389">
<prop type="lengthRatio">2.380952380952381</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety & reporting side effects</seg>
</tuv>
<tuv xml:lang="hr">
<seg>klinička ispitivanja;</seg>
</tuv>
</tu>
<tu tuid="390">
<prop type="lengthRatio">0.9555555555555556</prop>
<tuv xml:lang="en">
<seg>the eyes become red and sensitive to light;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>oči postanu crvene i osjetljive na svjetlost;</seg>
</tuv>
</tu>
<tu tuid="391">
<prop type="lengthRatio">1.1166666666666667</prop>
<tuv xml:lang="en">
<seg>on the third to seventh day, the temperature may reach up to 41 ⁰C;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>između trećeg i sedmog dana temperatura može rasti do 41 ⁰C;</seg>
</tuv>
</tu>
<tu tuid="392">
<prop type="lengthRatio">1.0297029702970297</prop>
<tuv xml:lang="en">
<seg>It is estimated that one person with measles can infect on average between 12 and 18 unprotected people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Procjenjuje se da jedna osoba zaražena ospicama može u prosjeku zaraziti 12 do 18 nezaštićenih osoba.</seg>
</tuv>
</tu>
<tu tuid="393">
<prop type="lengthRatio">1.0990990990990992</prop>
<tuv xml:lang="en">
<seg>The second dose can be given one month or more after the first dose, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Druga se doza može dati mjesec dana nakon prve doze ili kasnije, u skladu s nacionalnim rasporedom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="394">
<prop type="lengthRatio">0.8860759493670886</prop>
<tuv xml:lang="en">
<seg>It is a serious disease that can lead to complications and even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To je ozbiljna zarazna bolest koja može dovesti do komplikacija pa čak i smrti.</seg>
</tuv>
</tu>
<tu tuid="395">
<prop type="lengthRatio">1.0985915492957747</prop>
<tuv xml:lang="en">
<seg>The first dose is given between 10 and 18 months of age in European countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prva se doza u europskim zemljama daje između 10. i 18. mjeseca života.</seg>
</tuv>
</tu>
<tu tuid="396">
<prop type="lengthRatio">1.1458333333333333</prop>
<tuv xml:lang="en">
<seg>There is no cure for SSPE and it always leads to death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za SSPE nema lijeka te on uvijek završava smrću.</seg>
</tuv>
</tu>
<tu tuid="397">
<prop type="lengthRatio">0.9829059829059829</prop>
<tuv xml:lang="en">
<seg>Symptoms include personality changes, gradual mental deterioration, muscle spasms and other neuromuscular symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Simptomi uključuju promjene ličnosti, postupnu mentalnu degradaciju, grčenje mišića i druge neuromuskularne simptome.</seg>
</tuv>
</tu>
<tu tuid="398">
<prop type="lengthRatio">1.1240875912408759</prop>
<tuv xml:lang="en">
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stopa smrtnosti zbog ospica jest 1 - 3 osobe na 1000 slučajeva i najviša je među djecom mlađom od pet godina i imunosuprimiranim osobama.</seg>
</tuv>
</tu>
<tu tuid="399">
<prop type="lengthRatio">0.9693877551020408</prop>
<tuv xml:lang="en">
<seg>a red rash lasting four to seven days begins on the face and then spreads over the entire body;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>crveni osip koji traje četiri do sedam dana pojavljuje se na licu, a zatim širi po ostatku tijela;</seg>
</tuv>
</tu>
<tu tuid="400">
<prop type="lengthRatio">1.1162790697674418</prop>
<tuv xml:lang="en">
<seg>Virus-containing droplets can remain in the air for several hours and the virus remains infectious on contaminated surfaces for up to two hours.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kapljice zaražene virusom mogu ostati u zraku i nekoliko sati, a virus ostaje zarazan na kontaminiranim površinama i do dva sata.</seg>
</tuv>
</tu>
<tu tuid="401">
<prop type="lengthRatio">1.132867132867133</prop>
<tuv xml:lang="en">
<seg>Such dose before the age of nine months is supplementary to the two doses included in the national vaccination programme, which are aimed to give full protection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ta doza prije dobi od devet mjeseci dodatna je doza dvjema dozama iz nacionalnog programa cijepljenja, čiji je cilj osiguranje potpune zaštite.</seg>
</tuv>
</tu>
<tu tuid="402">
<prop type="lengthRatio">0.9354838709677419</prop>
<tuv xml:lang="en">
<seg>How can measles be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se ospice mogu spriječiti?</seg>
</tuv>
</tu>
<tu tuid="403">
<prop type="lengthRatio">1.131578947368421</prop>
<tuv xml:lang="en">
<seg>There is no specific treatment for measles.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ne postoji posebna terapija za ospice.</seg>
</tuv>
</tu>
<tu tuid="404">
<prop type="lengthRatio">0.9523809523809523</prop>
<tuv xml:lang="en">
<seg>Most people recover with supportive treatment, which can include hydration and anti-fever medicines.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina se osoba oporavi uz potpornu terapiju koja može uključivati hidrataciju i lijekove protiv vrućice.</seg>
</tuv>
</tu>
<tu tuid="405">
<prop type="lengthRatio">0.9739583333333334</prop>
<tuv xml:lang="en">
<seg>Infants from six to nine months of age who are in an area - or will be travelling to areas - with high risk of exposure to measles, should receive a supplementary dose of the MMR vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Dojenčad u dobi od šest do devet mjeseci starosti koja boravi na područjima s vrlo visokim rizikom od izloženosti ospicama ili će u ta područja putovati, treba dobiti dodatnu dozu cjepiva MMR.</seg>
</tuv>
</tu>
<tu tuid="406">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Measles symptoms usually appear after 10-12 days of infection:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Simptomi ospica obično se javljaju 10 do 12 dana nakon zaraze:</seg>
</tuv>
</tu>
<tu tuid="407">
<prop type="lengthRatio">1.0225563909774436</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR (protiv ospica, zaušnjaka i rubeole) kombinirano je cjepivo koje štiti od ospica, zaušnjaka i rubeole (njemačkih ospica).</seg>
</tuv>
</tu>
<tu tuid="408">
<prop type="lengthRatio">1.0676691729323309</prop>
<tuv xml:lang="en">
<seg>A person who is infected may transmit measles even before the rash appears (usually 4 days), and for about 4 days after the rash has appeared.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zaražena osoba može druge zaraziti ospicama čak i prije pojave osipa (obično četiri dana) i oko četiri dana nakon što se pojavi osip.</seg>
</tuv>
</tu>
<tu tuid="409">
<prop type="lengthRatio">0.8125</prop>
<tuv xml:lang="en">
<seg>Who is at risk of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od ospica?</seg>
</tuv>
</tu>
<tu tuid="410">
<prop type="lengthRatio">0.8522727272727273</prop>
<tuv xml:lang="en">
<seg>initial symptoms resemble a cold with a runny nose, cough and a mild fever;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>početni simptomi slični su onima prehlade s curenjem iz nosa, kašljem i blagom vrućicom;</seg>
</tuv>
</tu>
<tu tuid="411">
<prop type="lengthRatio">0.9259259259259259</prop>
<tuv xml:lang="en">
<seg>small white spots may also appear on the gums and the inside of the cheeks.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>sitna bijela zrnca također se mogu javiti na desnima i s unutarnje strane obraza.</seg>
</tuv>
</tu>
<tu tuid="412">
<prop type="lengthRatio">1.0948275862068966</prop>
<tuv xml:lang="en">
<seg>Very rarely, a persistent measles virus infection can produce subacute sclerosing panencephalitis (SSPE), a disease in which nerves and brain tissue degenerate progressively and which is more likely to appear if measles infection occurs at a younger age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Vrlo rijetko, perzistentna infekcija virusom ospica može uzrokovati subakutni sklerozirajući panencefalitis (SSPE), bolest kod koje živci i moždano tkivo progresivno degeneriraju te se češće javlja kod zaraze ospicama u mlađoj dobi.</seg>
</tuv>
</tu>
<tu tuid="413">
<prop type="lengthRatio">0.8981481481481481</prop>
<tuv xml:lang="en">
<seg>Pneumonia is a potential serious complication that has led to the death of some measles patients.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Upala pluća potencijalno je ozbiljna komplikacija koja je rezultirala smrću nekih osoba oboljelih od ospica.</seg>
</tuv>
</tu>
<tu tuid="414">
<prop type="lengthRatio">1.1590909090909092</prop>
<tuv xml:lang="en">
<seg>The only protection against measles is vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina je zaštita protiv ospica cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="415">
<prop type="lengthRatio">1.148936170212766</prop>
<tuv xml:lang="en">
<seg>Measles spreads easily among unvaccinated individuals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice se među necijepljenim osobama brzo šire.</seg>
</tuv>
</tu>
<tu tuid="416">
<prop type="lengthRatio">1.164179104477612</prop>
<tuv xml:lang="en">
<seg>Antibiotics are not effective against measles because it is caused by a virus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice se ne mogu liječiti antibioticima jer bolest uzrokuje virus.</seg>
</tuv>
</tu>
<tu tuid="417">
<prop type="lengthRatio">1.0207253886010363</prop>
<tuv xml:lang="en">
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Provodi se niz mjera za suzbijanje daljnjeg širenja ospica poput izostanka iz škole ili s posla i zaražene osobe i ostalih iz njegova okruženja, kao i osoba s nepotvrđenim statusom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="418">
<prop type="lengthRatio">1.0930232558139534</prop>
<tuv xml:lang="en">
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Otprilike jedna na 1000 osoba razvija upalu moždanih stanica (encefalitis), bolest čija je posljedica trajan neurološki invaliditet kod otprilike svakog četvrtog bolesnika.</seg>
</tuv>
</tu>
<tu tuid="419">
<prop type="lengthRatio">1.015267175572519</prop>
<tuv xml:lang="en">
<seg>SSPE typically appears several years after the affected patient had measles; on average it is seen 7 to 10 years after the infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>SSPE se obično javlja nekoliko godina nakon što je osoba preboljela ospice, u prosjeku sedam do deset godina nakon zaraze ospicama.</seg>
</tuv>
</tu>
<tu tuid="420">
<prop type="lengthRatio">0.9141104294478528</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7 - 14 days after vaccination, which disappears within 1 - 3 days.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih cijepljenih osoba razvija se neinfektivni blagi osip nalik ospicama, u pravilu 7 do 14 dana nakon cijepljenja, koji nestaje u roku od jednog do tri dana.</seg>
</tuv>
</tu>
<tu tuid="421">
<prop type="lengthRatio">1.0594059405940595</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice su vrlo zarazna virusna bolest od koje se može oboljeti u bilo kojoj dobi i koja se brzo širi.</seg>
</tuv>
</tu>
<tu tuid="422">
<prop type="lengthRatio">1.0816326530612246</prop>
<tuv xml:lang="en">
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, antibiotici se često primjenjuju za liječenje komplikacija ospica poput bakterijskih infekcija koje uključuju upalu pluća i infekcije uha.</seg>
</tuv>
</tu>
<tu tuid="423">
<prop type="lengthRatio">1.375</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi ospica?</seg>
</tuv>
</tu>
<tu tuid="424">
<prop type="lengthRatio">1.3571428571428572</prop>
<tuv xml:lang="en">
<seg>What are the complications of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije ospica?</seg>
</tuv>
</tu>
<tu tuid="425">
<prop type="lengthRatio">0.635593220338983</prop>
<tuv xml:lang="en">
<seg>30% of children and adults infected with measles can develop complications.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije se mogu razviti kod 30 % djece i odraslih zaraženih ospicama te mogu uključivati infekcije uha i proljev.</seg>
</tuv>
</tu>
<tu tuid="426">
<prop type="lengthRatio">1.1428571428571428</prop>
<tuv xml:lang="en">
<seg>What is measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što su ospice?</seg>
</tuv>
</tu>
<tu tuid="427">
<prop type="lengthRatio">1.2409638554216869</prop>
<tuv xml:lang="en">
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Virus ospica širi se zrakom kapljicama koje iskašljavaju ili izdišu zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="428">
<prop type="lengthRatio">1.1</prop>
<tuv xml:lang="en">
<seg>How is measles spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se ospice šire?</seg>
</tuv>
</tu>
<tu tuid="429">
<prop type="lengthRatio">0.7848101265822784</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine may be given earlier in life during outbreaks.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tijekom izbijanja epidemija ospica cjepivo MMR može se davati i u ranijoj dobi.</seg>
</tuv>
</tu>
<tu tuid="430">
<prop type="lengthRatio">0.7228915662650602</prop>
<tuv xml:lang="en">
<seg>Pneumonia is the most common cause of measles-related death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Upala pluća koja je rezultirala smrću najčešća je komplikacija uzrokovana ospicama.</seg>
</tuv>
</tu>
<tu tuid="431">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>How is measles treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se ospice liječe?</seg>
</tuv>
</tu>
<tu tuid="432">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Riziku od ospica izložene su osobe svih dobi koje nisu cijepljenje protiv ospica ili ih nisu preboljele.</seg>
</tuv>
</tu>
<tu tuid="433">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>It provides options for the user to filter information by criteria such as disease and time-period.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Korisnicima nudi mogućnost filtriranja informacija prema kriterijima kao što su bolest i razdoblje.</seg>
</tuv>
</tu>
<tu tuid="434">
<prop type="lengthRatio">1.0175438596491229</prop>
<tuv xml:lang="en">
<seg>The data is based on information submitted and verified by Member States through ECDC's disease surveillance system.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Temelje se na informacijama koje su dostavile i potvrdile države članice putem ECDC-ova sustava za nadzor bolesti.</seg>
</tuv>
</tu>
<tu tuid="435">
<prop type="lengthRatio">0.94375</prop>
<tuv xml:lang="en">
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ECDC-ov atlas za nadzor zaraznih bolesti sadržava podatke i o drugim bolestima koje je moguće spriječiti cijepljenjem, kao što su difterija, hripavac i rubeola.</seg>
</tuv>
</tu>
<tu tuid="436">
<prop type="lengthRatio">0.8275862068965517</prop>
<tuv xml:lang="en">
<seg>Below are the most recent data on measles outbreaks in EU Member States.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nastavku su prikazani najnoviji podatci o izbijanju ospica u državama članicama EU-a.</seg>
</tuv>
</tu>
<tu tuid="437">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Situation of measles in the EU</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stanje u EU-u u pogledu ospica</seg>
</tuv>
</tu>
<tu tuid="438">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Serious side effects are very rare.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ozbiljne nuspojave jako su rijetke.</seg>
</tuv>
</tu>
<tu tuid="439">
<prop type="lengthRatio">1.121212121212121</prop>
<tuv xml:lang="en">
<seg>The first vaccine was developed in the 18th century in the United Kingdom.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prvo cjepivo razvijeno je u 18. stoljeću u Ujedinjenoj Kraljevini.</seg>
</tuv>
</tu>
<tu tuid="440">
<prop type="lengthRatio">0.8089887640449438</prop>
<tuv xml:lang="en">
<seg>The last known naturally occurring case was recorded in 1977 in Somalia.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Posljednji poznati slučaj prirodne pojave velikih boginja zabilježen je 1977. u Somaliji.</seg>
</tuv>
</tu>
<tu tuid="441">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>The vaccine is continuously monitored to ensure it remains safe and effective.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo se neprestano prati kako bi i nadalje bilo sigurno i učinkovito.</seg>
</tuv>
</tu>
<tu tuid="442">
<prop type="lengthRatio">1.03125</prop>
<tuv xml:lang="en">
<seg>They also help to prevent the spread of diseases in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osim toga pomažu i kod sprječavanja širenja bolesti u zajednici.</seg>
</tuv>
</tu>
<tu tuid="443">
<prop type="lengthRatio">0.7532467532467533</prop>
<tuv xml:lang="en">
<seg>They mainly target diseases caused by viruses or bacteria.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uglavnom se upotrebljavaju protiv bolesti uzrokovanih virusima i bakterijama.</seg>
</tuv>
</tu>
<tu tuid="444">
<prop type="lengthRatio">1.089171974522293</prop>
<tuv xml:lang="en">
<seg>The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully, in particular because vaccines are given to healthy people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Znanstvenici koji ocjenjuju cjepiva uvijek vrlo pažljivo razmatraju koristi i sve potencijalne rizike, osobito zbog toga što se cjepivo daje zdravim ljudima.</seg>
</tuv>
</tu>
<tu tuid="445">
<prop type="lengthRatio">1.0707964601769913</prop>
<tuv xml:lang="en">
<seg>As with any medicine, some people may experience side effects from a vaccine, but these are usually mild and short-lived.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kao i kod svakog lijeka kod nekih osoba mogu nastupiti nuspojave cjepiva, ali one su obično blage i kratkotrajne.</seg>
</tuv>
</tu>
<tu tuid="446">
<prop type="lengthRatio">0.9215686274509803</prop>
<tuv xml:lang="en">
<seg>Only then, after approval, can a vaccine be manufactured, marketed and used to protect people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tek nakon odobrenja cjepivo se može proizvoditi, stavljati u promet i upotrebljavati za zaštitu ljudi.</seg>
</tuv>
</tu>
<tu tuid="447">
<prop type="lengthRatio">0.9459459459459459</prop>
<tuv xml:lang="en">
<seg>They can include mild fever, or pain or redness at the injection site.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To mogu biti blaga vrućica, bol ili crvenilo na mjestu primjene injekcije.</seg>
</tuv>
</tu>
<tu tuid="448">
<prop type="lengthRatio">0.7717391304347826</prop>
<tuv xml:lang="en">
<seg>Before any new vaccine can be used, it has to undergo rigorous testing.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije nego što se bilo koje novo cjepivo počne primjenjivati, mora proći stroga ispitivanja.</seg>
</tuv>
</tu>
<tu tuid="449">
<prop type="lengthRatio">1.1140350877192982</prop>
<tuv xml:lang="en">
<seg>Vaccines work by ‘teaching' a person's immune system (the body's natural defences) to defend itself against a specific disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva djeluju tako što uče imunosni sustav (prirodnoj obrani tijela) osobe kako se obraniti od određene bolesti.</seg>
</tuv>
</tu>
<tu tuid="450">
<prop type="lengthRatio">1.072</prop>
<tuv xml:lang="en">
<seg>This evaluation needs to show that a vaccine's benefits in protecting people against diseases are far greater than any potential risk.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ocjenjivanjem je potrebo utvrditi da su koristi cjepiva za zaštitu ljudi od bolesti daleko veće od svih potencijalnih rizika.</seg>
</tuv>
</tu>
<tu tuid="451">
<prop type="lengthRatio">1.0476190476190477</prop>
<tuv xml:lang="en">
<seg>Recently, a vaccine was developed against Ebola virus disease, and research is underway on vaccines to protect against human immunodeficiency virus (HIV).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nedavno je razvijeno cjepivo protiv virusne bolesti ebole, a u tijeku je istraživanje cjepiva za zaštitu od virusa humane imunodeficijencije (HIV).</seg>
</tuv>
</tu>
<tu tuid="452">
<prop type="lengthRatio">1.0681818181818181</prop>
<tuv xml:lang="en">
<seg>Nowadays, there are vaccines for many diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Danas postoje cjepiva protiv mnogih bolesti.</seg>
</tuv>
</tu>
<tu tuid="453">
<prop type="lengthRatio">1.2247191011235956</prop>
<tuv xml:lang="en">
<seg>Vaccines are used worldwide as a highly effective way to protect people from contracting infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva se diljem svijeta upotrebljavaju kao vrlo učinkovita zaštita od zaraznih bolesti.</seg>
</tuv>
</tu>
<tu tuid="454">
<prop type="lengthRatio">0.9117647058823529</prop>
<tuv xml:lang="en">
<seg>Research is ongoing to develop vaccines against more diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tijeku su istraživanja za razvoj cjepiva protiv još nekih bolesti.</seg>
</tuv>
</tu>
<tu tuid="455">
<prop type="lengthRatio">0.8387096774193549</prop>
<tuv xml:lang="en">
<seg>It was a vaccine against smallpox, a deadly disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bilo je to cjepivo protiv velikih boginja, smrtonosne bolesti.</seg>
</tuv>
</tu>
<tu tuid="456">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Činjenice o cjepivu</seg>
</tuv>
</tu>
<tu tuid="457">
<prop type="lengthRatio">0.9631336405529954</prop>
<tuv xml:lang="en">
<seg>The vaccine can only be approved for use in the European Union (EU) and European Economic Area (EEA) after a scientific evaluation of the results of these tests to ensure its quality, safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tek nakon znanstvene ocjene rezultata tih ispitivanja kojima se osigurava kvaliteta, sigurnost i učinkovitost cjepiva, ono može biti odobreno za primjenu u Europskoj uniji (EU) i Europskom gospodarskom prostoru (EGP).</seg>
</tuv>
</tu>
<tu tuid="458">
<prop type="lengthRatio">0.5087719298245614</prop>
<tuv xml:lang="en">
<seg>Safety, quality and standards</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Praćenje sigurnosti cjepiva i izvješćivanje o nuspojavama</seg>
</tuv>
</tu>
<tu tuid="459">
<prop type="lengthRatio">0.8625</prop>
<tuv xml:lang="en">
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju velike boginje u ljudi iskorijenjene su diljem svijeta.</seg>
</tuv>
</tu>
<tu tuid="460">
<prop type="lengthRatio">0.8857142857142857</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Odobrenje cjepiva u Europskoj uniji</seg>
</tuv>
</tu>
<tu tuid="461">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>In some countries such recommendations are done at state or regional level.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se zemljama te preporuke daju na razini saveznih država ili regija.</seg>
</tuv>
</tu>
<tu tuid="462">
<prop type="lengthRatio">1.0434782608695652</prop>
<tuv xml:lang="en">
<seg>Some vaccines are not part of routine vaccination schedules but are targeted at specific groups.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neka cjepiva nisu dio rutinskih programa cijepljenja, već su namijenjena posebnim skupinama.</seg>
</tuv>
</tu>
<tu tuid="463">
<prop type="lengthRatio">0.9553571428571429</prop>
<tuv xml:lang="en">
<seg>In addition, vaccines to protect against specific diseases are sometimes recommended for ‘high-risk' groups, such as people with long-term health conditions or people planning to travel to other parts of the world.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osim toga, cjepiva koja štite od određenih bolesti katkad se preporučuju za skupine izložene „visokom riziku", kao što su osobe s dugotrajnim zdravstvenim problemima ili osobe koji planiraju putovati u druge krajeve svijeta.</seg>
</tuv>
</tu>
<tu tuid="464">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>Decisions on vaccines in use in different European countries</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Odluke o cjepivima koja se primjenjuju u različitim europskim zemljama</seg>
</tuv>
</tu>
<tu tuid="465">
<prop type="lengthRatio">1.0202702702702702</prop>
<tuv xml:lang="en">
<seg>Healthcare professionals (e.g. doctors, nurses) have a role in ensuring that patients in their care receive the recommended vaccines at the right time.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uloga je zdravstvenih radnika (npr. liječnika i medicinskih sestara) zajamčiti da pacijenti u njihovoj skrbi pravovremeno prime preporučena cjepiva.</seg>
</tuv>
</tu>
<tu tuid="466">
<prop type="lengthRatio">1.0390625</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age groups, often for infants and children, but also for teenagers, adults and elderly people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva se preporučuju za različite dobne skupine, često za novorođenčad i djecu, ali i za adolescente, odrasle i starije osobe.</seg>
</tuv>
</tu>
<tu tuid="467">
<prop type="lengthRatio">1.0130718954248366</prop>
<tuv xml:lang="en">
<seg>For example, people who travel to regions where certain infectious diseases circulate such as yellow fever and typhoid fever may need to have vaccinations.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Primjerice, osobe koje putuju u područja u kojima kolaju određene zarazne bolesti, poput žute groznice ili tifusne groznice, možda će se morati cijepiti.</seg>
</tuv>
</tu>
<tu tuid="468">
<prop type="lengthRatio">1.488888888888889</prop>
<tuv xml:lang="en">
<seg>They also provide recommendations for people with chronic diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Usto, izdaju preporuke za kronične bolesnike.</seg>
</tuv>
</tu>
<tu tuid="469">
<prop type="lengthRatio">0.9514563106796117</prop>
<tuv xml:lang="en">
<seg>This is based on local conditions, such as how common the disease is, as well as economic factors.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To ovisi o lokalnim uvjetima, kao što su učestalost određene bolesti, ali i o gospodarskim čimbenicima.</seg>
</tuv>
</tu>
<tu tuid="470">
<prop type="lengthRatio">0.7627118644067796</prop>
<tuv xml:lang="en">
<seg>Some countries require proof of certain vaccinations before granting entry to the country.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neke zemlje zahtijevaju dokaz o cijepljenju protiv određenih bolesti prije nego što putnicima dopuste ulazak u zemlju.</seg>
</tuv>
</tu>
<tu tuid="471">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Sometimes, more than one vaccine may be given at once to protect against several infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Katkad je moguće dati više cjepiva odjednom kako bi se postigla zaštita od nekoliko zaraznih bolesti.</seg>
</tuv>
</tu>
<tu tuid="472">
<prop type="lengthRatio">0.8387096774193549</prop>
<tuv xml:lang="en">
<seg>Combined use of vaccines is well established and based on scientific studies on its benefits and safety.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kombinirana primjena cjepiva uvriježena je praksa i temelji se na znanstvenim istraživanjima o koristi i sigurnosti cjepiva.</seg>
</tuv>
</tu>
<tu tuid="473">
<prop type="lengthRatio">1.1153846153846154</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osnovna je svrha ovog mrežnog mjesta pružiti točne, objektivne i ažurne podatke o cjepivu i cijepljenju.</seg>
</tuv>
</tu>
<tu tuid="474">
<prop type="lengthRatio">1.1695906432748537</prop>
<tuv xml:lang="en">
<seg>Each factsheet provides key facts about a disease, with an overview of the symptoms, complications, how the disease spreads, who is at risk, how the disease can be prevented and how it can be treated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaki članak sadrži ključne činjenice o bolesti s informacijama o simptomima, komplikacijama, načinu širenja, ugroženim skupinama, sprječavanju bolesti i načinu liječenja.</seg>
</tuv>
</tu>
<tu tuid="475">
<prop type="lengthRatio">0.9716312056737588</prop>
<tuv xml:lang="en">
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina nacionalnih programa cijepljenja u EU-u/EGP-u obuhvaća cjepiva protiv najviše dvadeset bolesti koja se daju u određenoj životnoj dobi.</seg>
</tuv>
</tu>
<tu tuid="476">
<prop type="lengthRatio">1.0229885057471264</prop>
<tuv xml:lang="en">
<seg>Some vaccines protect against only one disease, but others protect against more than one.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pojedina cjepiva štite od samo jedne bolesti, dok druga cjepiva štite od nekoliko njih.</seg>
</tuv>
</tu>
<tu tuid="477">
<prop type="lengthRatio">1.1633986928104576</prop>
<tuv xml:lang="en">
<seg>Vaccination also reduces the risk of spreading the diseases among family members, school mates or colleagues, friends and neighbours, as well as to other people in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se smanjuje rizik od širenja bolesti među članovima obitelji, učenicima ili kolegama, prijateljima i susjedima i drugim ljudima u zajednici.</seg>
</tuv>
</tu>
<tu tuid="478">
<prop type="lengthRatio">0.9649122807017544</prop>
<tuv xml:lang="en">
<seg>To learn more about the diseases that can be prevented by vaccination, consult the factsheets available below.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Da biste saznali više o bolestima koje se mogu spriječiti cijepljenjem, pročitajte informativne članke u nastavku.</seg>
</tuv>
</tu>
<tu tuid="479">
<prop type="lengthRatio">0.9712643678160919</prop>
<tuv xml:lang="en">
<seg>For more information about national vaccination programmes, see the ECDC vaccine scheduler and visit the official websites on immunisation of the EU/EEA countries here .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija o nacionalnim programima cijepljenja potražite u Kalendaru cijepljenja ECDC-a , a službene mrežne stranice zemalja EU-a/EGP-a o imunizaciji posjetite ovdje .</seg>
</tuv>
</tu>
<tu tuid="480">
<prop type="lengthRatio">0.7295597484276729</prop>
<tuv xml:lang="en">
<seg>National vaccination schedules in EU/EEA countries recommend vaccines at specific ages and for specific populations.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U okviru svojih nacionalnih programa cijepljenja države na području EU-a/EGP-a preporučuju cjepiva u određenoj životnoj dobi i za određene dijelove populacije.</seg>
</tuv>
</tu>
<tu tuid="481">
<prop type="lengthRatio">1.0825688073394495</prop>
<tuv xml:lang="en">
<seg>Thanks to vaccination, people can be protected against diseases that could have serious consequences for their health.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju, ljudi se mogu zaštititi od bolesti koje mogu imati ozbiljne posljedice za zdravlje.</seg>
</tuv>
</tu>
<tu tuid="482">
<prop type="lengthRatio">0.8895705521472392</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih cijepljenih osoba razvija se neinfektivni blagi osip nalik ospicama, u pravilu 7 do 14 dana nakon cijepljenja, koji nestaje u roku od jednog do tri dana.</seg>
</tuv>
</tu>
<tu tuid="483">
<prop type="lengthRatio">1.1568627450980393</prop>
<tuv xml:lang="en">
<seg>Nowadays, several diseases can be prevented by vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem danas možemo spriječiti razne bolesti.</seg>
</tuv>
</tu>
<tu tuid="484">
<prop type="lengthRatio">0.9125</prop>
<tuv xml:lang="en">
<seg>Factsheets of five vaccine- preventable diseases are currently available.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Dosad smo objavili pet članaka o bolestima koje se mogu spriječiti cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="485">
<prop type="lengthRatio">0.95</prop>
<tuv xml:lang="en">
<seg>What are the complications of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije izazvane hripavcem?</seg>
</tuv>
</tu>
<tu tuid="486">
<prop type="lengthRatio">0.9915254237288136</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko tko nije cijepljen protiv hripavca ili tko nije primio sve potrebne doze cjepiva može se zaraziti ovom bolešću.</seg>
</tuv>
</tu>
<tu tuid="487">
<prop type="lengthRatio">0.46629213483146065</prop>
<tuv xml:lang="en">
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To je poznato pod nazivom „kolektivna imunost" (koja se ponekad još naziva i „imunost krda") Cijepljenjem je moguće iskorijeniti bolesti ili znatno smanjiti broj novih slučajeva.</seg>
</tuv>
</tu>
<tu tuid="488">
<prop type="lengthRatio">0.5253456221198156</prop>
<tuv xml:lang="en">
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako želite više informacija o toj mreži, posjetite: https://vaccinesafetynet.org . Informacije o članicama mreže VSN i poveznice na njihova mrežna mjesta dostupne su ovdje: https://www.vaccinesafetynet.org/vsn/network</seg>
</tuv>
</tu>
<tu tuid="489">
<prop type="lengthRatio">0.9803921568627451</prop>
<tuv xml:lang="en">
<seg>More factsheets will be included at a later stage.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>S vremenom ćemo dodavati članke o drugim bolestima.</seg>
</tuv>
</tu>
<tu tuid="490">
<prop type="lengthRatio">0.7045454545454546</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europski portal za informacije o cijepljenju</seg>
</tuv>
</tu>
<tu tuid="491">
<prop type="lengthRatio">1.0357142857142858</prop>
<tuv xml:lang="en">
<seg>Safety, quality and standards</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Sigurnost, kvaliteta i norme</seg>
</tuv>
</tu>
<tu tuid="492">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV)</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Humani papilomavirus (HPV)</seg>
</tuv>
</tu>
<tu tuid="493">
<prop type="lengthRatio">1.2222222222222223</prop>
<tuv xml:lang="en">
<seg>The Vaccine Safety Net</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Vaccine Safety Net</seg>
</tuv>
</tu>
<tu tuid="494">
<prop type="lengthRatio">1.2820512820512822</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Izvor: Plotkin S, Orenstein W, Offit P.</seg>
</tuv>
</tu>
<tu tuid="495">
<prop type="lengthRatio">0.8645833333333334</prop>
<tuv xml:lang="en">
<seg>The Commission is divided into departments that develop policies in specific areas.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komisija je organizirana na temelju glavnih uprava koje razvijaju politiku za određena područja.</seg>
</tuv>
</tu>
<tu tuid="496">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>What is HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je HPV?</seg>
</tuv>
</tu>
<tu tuid="497">
<prop type="lengthRatio">1.035294117647059</prop>
<tuv xml:lang="en">
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih osoba cjepivo može biti kontraindicirano, što znači da ga ne smiju primiti.</seg>
</tuv>
</tu>
<tu tuid="498">
<prop type="lengthRatio">1.1181102362204725</prop>
<tuv xml:lang="en">
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rak grlića maternice najčešća je vrsta raka, nakon raka dojke, od koje obolijevaju žene u Europi u dobi od 15 do 44 godine (1).</seg>
</tuv>
</tu>
<tu tuid="499">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>What is rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je rubeola?</seg>
</tuv>
</tu>
<tu tuid="500">
<prop type="lengthRatio">0.8513513513513513</prop>
<tuv xml:lang="en">
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cilj je inicijative odgovoriti na oklijevanje s cijepljenjem, poboljšati koordinaciju u nabavi cjepiva, podržati istraživanje i razvoj te ojačati suradnju unutar EU-a u pogledu bolesti koje se mogu spriječiti cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="501">
<prop type="lengthRatio">0.8507462686567164</prop>
<tuv xml:lang="en">
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Informacije o članicama mreže VSN i poveznice na njihova mrežna mjesta dostupne su ovdje: https://www.vaccinesafetynet.org/vsn/network</seg>
</tuv>
</tu>
<tu tuid="502">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>The ‘high risk' HPV types can also cause anal and genital cancers, and some cancers of the head and neck, in both men and women.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>„Visokorizične" vrste HPV-a mogu uzrokovati i rak anusa i genitalija te neke vrste raka glave i vrata, neovisno o spolu.</seg>
</tuv>
</tu>
<tu tuid="503">
<prop type="lengthRatio">1.1827956989247312</prop>
<tuv xml:lang="en">
<seg>Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije cijepljenja uvijek se potrebno posavjetovati s liječnikom oko mogućih kontraindikacija.</seg>
</tuv>
</tu>
<tu tuid="504">
<prop type="lengthRatio">0.926829268292683</prop>
<tuv xml:lang="en">
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako želite više informacija o toj mreži, posjetite: https://vaccinesafetynet.org .</seg>
</tuv>
</tu>
<tu tuid="505">
<prop type="lengthRatio">1.4285714285714286</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije ospica?</seg>
</tuv>
</tu>
<tu tuid="506">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>How is measles spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac širi?</seg>
</tuv>
</tu>
<tu tuid="507">
<prop type="lengthRatio">0.9583333333333334</prop>
<tuv xml:lang="en">
<seg>How is measles treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac liječi?</seg>
</tuv>
</tu>
<tu tuid="508">
<prop type="lengthRatio">0.972027972027972</prop>
<tuv xml:lang="en">
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu provoditi i ispitivanja kako bi bila sigurna da su serije cjepiva stavljene u promet odgovarajuće kvalitete te da su ispravno proizvedene.</seg>
</tuv>
</tu>
</body>
</tmx>
|